# EDGAR Filing Document

**Accession Number:** 0001844817
**File Stem:** 0001193125-23-039389
**Filing Date:** 2023-2
**Character Count:** 172099
**Document Hash:** f350dce81ffa1a4996925659715cdec8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-039389.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001193125-23-039389

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 41

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Armada Acquisition Corp. I
- **CENTRAL INDEX KEY:** 0001844817
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 853810850
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40742
- **FILM NUMBER:** 23631757

**BUSINESS ADDRESS:**
- **STREET 1:** 1760 MARKET STREET
- **STREET 2:** SUITE 602
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103
- **BUSINESS PHONE:** (215) 543-6886

**MAIL ADDRESS:**
- **STREET 1:** 1760 MARKET STREET
- **STREET 2:** SUITE 602
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19103

?xml version="1.0" encoding="utf-8" ? 10-Q

##### [**Table of Contents**](#toc)
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Commission File No. 001-40742

Armada Acquisition Corp. I

(Exact name of registrant as specified in its charter)

Delaware 85-3810850 <br> (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.)

1760 Market Street, Suite 602

Philadelphia, PA 19103

(Address of Principal Executive Offices, including zip code)

(215) 543-6886

(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br>Symbol(s) | Name of each exchange<br>on which registered |
| Units, each consisting of one share of Common Stock and one-half of one Redeemable Warrant | AACIU | The Nasdaq Stock Market LLC |
| Common Stock, par value $0.0001 per share | AACI | The Nasdaq Stock Market LLC |
| Warrants, each exercisable for one share of Common Stock for $11.50 per share | AACIW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| ☐ | Large accelerated filer | ☐ | Accelerated filer |
| ☒ | Non-accelerated filer | ☒ | Smaller reporting company |
|  |  | ☒ | Emerging growth company |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

At February 14, 2023, there were 20,709,500 shares of Common Stock, $0.0001 par value per share ("Common Stock"), issued and outstanding which includes shares of Common Stock underlying the Units sold in the registrant's initial public offering and of which 20,585,251 shares of Common stock trade separately.

------

##### [**Table of Contents**](#toc)

#### ARMADA ACQUISITION CORP. I

#### Quarterly Report on Form 10-Q

#### **Table of Contents**

---

| | | |
|:---|:---|:---|
|  PART I. FINANCIAL INFORMATION | PART I. FINANCIAL INFORMATION | PART I. FINANCIAL INFORMATION |
|  Item 1. | [Financial Statements](#fin431131_1) | 1 |
|  | [Condensed Balance Sheets as of December 31, 2022 (Unaudited) and September 30, 2022 (Audited)](#fin431131_2) | 1 |
|  | [Condensed Statements of Operations for the three months ended December 31, 2022 and 2021 (Unaudited)](#fin431131_3) | 2 |
|  | [Condensed Statements of Changes in Stockholders' Deficit for the three months ended December 31, 2022 and 2021 (Unaudited)](#fin431131_4) | 3 |
|  | [Condensed Statements of Cash Flows for the three months ended December 31, 2022 and 2021 (Unaudited)](#fin431131_5) | 4 |
|  | [Notes to Unaudited Condensed Financial Statements](#fin431131_6) | 5 |
|  Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#fin431131_7) | 18 |
|  Item 3. | [Quantitative and Qualitative Disclosures About Market Risk](#fin431131_8) | 25 |
|  Item 4. | [Controls and Procedures](#fin431131_9) | 26 |
|  PART II. OTHER INFORMATION | PART II. OTHER INFORMATION | PART II. OTHER INFORMATION |
|  Item 1. | [Legal Proceedings](#fin431131_10) | 27 |
|  Item 1A. | [Risk Factors](#fin431131_11) | 27 |
|  Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#fin431131_12) | 27 |
|  Item 3. | [Defaults Upon Senior Securities](#fin431131_13) | 27 |
|  Item 4. | [Mine Safety Disclosures](#fin431131_14) | 27 |
|  Item 5. | [Other Information](#fin431131_15) | 27 |
|  Item 6. | [Exhibits](#fin431131_16) | 27 |
|  [SIGNATURES](#fin431131_17) | [SIGNATURES](#fin431131_17) | 30 |

---

------

##### [**Table of Contents**](#toc)
PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

ARMADA ACQUISITION CORP. I

CONDENSED BALANCE SHEETS

---

| | | |
|:---|:---|:---|
|  | December 31,<br> 2022 | September 30,<br> 2022 |
|  | (Unaudited) | (Audited) |
| Assets |  |  |
| Cash | $363247 | $177578 |
| Prepaid expenses | 6264 | 61942 |
| Total current assets | 369511 | 239520 |
| Investment held in Trust Account | 153634598 | 150844925 |
| Total Assets | $154004109 | $151084445 |
| Liabilities, Common Stock Subject to Possible Redemption and Stockholders' Deficit |  |  |
| Current liabilities: |  |  |
| Accounts payable | $3161878 | $3137535 |
| Franchise tax payable | 200000 | 150000 |
| Income tax payable | 405952 | 145621 |
| Promissory Notes-Related Party | 2201754 | 251754 |
| Total current liabilities | 5969584 | 3684910 |
| Commitments and Contingencies (Note 4) |  |  |
| Common stock subject to possible redemption, 15,000,000 shares at redemption value of $10.20 and $10.04 per share at December 31, 2022 and September 30, 2022, respectively | 153028205 | 150548862 |
| Stockholders' Deficit: |  |  |
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding |  |  |
| Common stock, $0.0001 par value; 100,000,000 shares authorized, 5,709,500 shares issued and outstanding (excluding 15,000,000 shares subject to possible redemption) at December 31, 2022 and September 30, 2022 | 570 | 570 |
| Additional paid-in capital | 969759 | 941796 |
| Accumulated deficit | (5964009) | (4091693) |
| Total Stockholders' Deficit | (4993680) | (3149327) |
| Total Liabilities, Common Stock Subject to Possible Redemption and Stockholders' Deficit | $154004109 | $151084445 |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

------

#### **Table of Contents**
ARMADA ACQUISITION CORP. I

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | Three months ended | Three months ended |
|  | December 31, 2022 | December 31, 2021 |
| Formation and operating costs | $394352 | $2010995 |
| Stock-based compensation | 27963 | 27963 |
| Loss from operations | (422315) | (2038958) |
| Other income |  |  |
| Trust interest income | 1289673 | 2844 |
| Total other income | 1289673 | 2844 |
| Income (loss) before provision for income taxes | 867358 | (2036114) |
| Provision for income taxes | (260331) |  |
| Net income (loss) | $607027 | $(2036114) |
| Basic and diluted weighted average shares outstanding, common stock subject to possible redemption | 15000000 | 15000000 |
| Basic and diluted net income (loss) per share | $0.03 | $(0.10) |
| Basic and diluted weighted average shares outstanding, non-redeemable common stock | 5709500 | 5709500 |
| Basic and diluted net income (loss) per share | $0.03 | $(0.10) |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

------

ARMADA ACQUISITION CORP. I

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

(Unaudited)

THREE MONTHS ENDED DECEMBER 31, 2022

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Common Stock | Common Stock | Additional<br> Paid-in Capital | Accumulated<br> Deficit | Total<br> Stockholders'<br> Deficit |
|  | Shares | Amount | Additional<br> Paid-in Capital | Accumulated<br> Deficit | Total<br> Stockholders'<br> Deficit |
| Balance as of September 30, 2022 (audited) | 5709500 | $570 | $941796 | $(4091693) | $(3149327) |
| Stock-based compensation |  |  | 27963 |  | 27963 |
| Subsequent remeasurement of common stock subject to possible redemption |  |  |  | (2479343) | (2479343) |
| Net income |  |  |  | 607027 | 607027 |
| Balance as of December 31, 2022 | 5709500 | $570 | $969759 | $(5964009) | $(4993680) |

---

FOR THE THREE MONTHS ENDED DECEMBER 31, 2021

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Common Stock | Common Stock | Additional<br> Paid-in<br> Capital | Accumulated<br> Deficit | Total<br> Stockholders'<br> Equity<br> (Deficit) |
|  | Shares | Amount | Additional<br> Paid-in<br> Capital | Accumulated<br> Deficit | Total<br> Stockholders'<br> Equity<br> (Deficit) |
| Balance as of September 31, 2021 (audited) | 6834500 | $683 | $1378693 | $(468899) | $910477 |
| Forfeiture of founder shares | (1125000) | (113) | 113 |  |  |
| Stock-based compensation |  |  | 27963 |  | 27963 |
| Net loss |  |  |  | (2036114) | (2036114) |
| Balance as of December 31, 2021 | 5709500 | $570 | $1406769 | $(2505013) | $(1097674) |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

------

ARMADA ACQUISITION CORP. I

UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | Three months ended<br> December 31, 2022 | Three months ended<br> December 31, 2021 |
| Cash Flows from Operating Activities: |  |  |
| Net income (loss) | $607027 | $(2036114) |
|  Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |
| Interest earned on investments held in Trust Account | (1289673) | (2844) |
| Stock-based compensation | 27963 | 27963 |
| Changes in current assets and liabilities: |  |  |
| Prepaid expenses | 55678 | 120574 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable  | 24344 | 1603681 |
| Income tax payable | 260331 |  |
| Franchise tax payable | 50000 | 48850 |
| Net cash used in operating activities | (264331) | (237890) |
| Cash Flows from Investing Activities: |  |  |
| Principal deposited in Trust Account | (1500000) |  |
| Net cash used in investing activities | (1500000) |  |
| Cash Flows from Financing Activities: |  |  |
| Proceeds from issuance of promissory notes to related party | 1950000 |  |
| Advances from related parties |  |  |
| Payment of deferred offering costs |  |  |
| Net cash provided by financing activities | 1950000 |  |
| Net change in cash | 185669 | (237890) |
| Cash, beginning of the period | 177578 | 657590 |
| Cash, end of the period | $363247 | $419700 |
| Supplemental disclosure of noncash investing and financing activities |  |  |
| Subsequent remeasurement of common stock subject to possible redemption | $2479343 | $— |

---

The accompanying notes are an integral part of these unaudited condensed financial statements.

------

ARMADA ACQUISITION CORP. I

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Note 1 — Organization, Business Operations and Going Concern

Armada Acquisition Corp. I (the "Company") is a blank check company incorporated as a Delaware corporation on November 5, 2020. The Company was incorporated for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the "Business Combination"). As more fully described in this Note 1, on December 17, 2021, the Company entered into a business combination agreement with a target business. The Company concentrated its efforts in identifying businesses in the financial services industry with particular emphasis on businesses that are providing or changing technology for traditional financial services.

As of December 31, 2022, the Company had not commenced any operations. All activity for the period from November 5, 2020 (inception) through December 31, 2022, relates to the Company's formation and the initial public offering (the "IPO") described below, and since the closing of the IPO, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the IPO.

The Company's sponsor is Armada Sponsor LLC (the "Sponsor").

The registration statement for the Company's IPO was declared effective on August 12, 2021 (the "Effective Date"). On August 17, 2021, the Company commenced the IPO of 15,000,000 units at $10.00 per unit (the "Units").

Simultaneously with the consummation of the IPO, the Company consummated the private placement of 459,500 shares of common stock ("Private Shares"), at a price of $10.00 per share for an aggregate purchase price of $4,595,000.

Transaction costs amounted to $3,537,515 consisting of $1,500,000 of underwriting commissions, and $2,037,515 of other offering costs.

Following the closing of the IPO on August 17, 2021, after releasing funds to the Company to be held outside of the Trust, $150,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO was held in a Trust Account ("Trust Account") and has been invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the "Investment Company Act"), having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay tax obligations, the proceeds from the IPO and the sale of the Private Shares will not be released from the Trust Account until the earlier of the completion of a Business Combination or the Company's redemption of 100% of the outstanding public shares if it has not completed a Business Combination in the required time period The proceeds held in the Trust Account may be used as consideration to pay the sellers of a target business with which the Company completes a Business Combination. Any amounts not paid as consideration to the sellers of the target business may be used to finance operations of the target business. As of December 31, 2022, the Trust Account has released $182,069 to the Company to pay tax obligations.

The Company's management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of Private Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.

The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the value of the assets held in the trust account (as defined below) (excluding deferred underwriting commissions and taxes payable) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to complete a Business Combination successfully.

------

In connection with any proposed Business Combination, the Company will either (1) seek stockholders approval of the initial Business Combination at a meeting called for such purpose at which stockholders may seek to redeem their shares, regardless of whether they vote for or against the proposed Business Combination or don't vote at all, into their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable), or (2) provide its stockholders with the opportunity to sell their shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable), in each case subject to the limitations described herein. The decision as to whether the Company will seek stockholders approval of a proposed Business Combination or will allow stockholders to sell their shares to the Company in a tender offer will be made by the Company, solely in its discretion.

The shares of common stock subject to redemption are recorded at a redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification ("ASC") Topic 480 "Distinguishing Liabilities from Equity." In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.

Following the exercise of the automatic extension of the deadline for the Company to complete an initial business combination under our second amended and restated certificate of incorporation, the Company had until February 17, 2023 (or 18 months following our initial public offering) to consummate a business combination (unless we further extend the period of time to consummate a business combination) (the "Combination Period"). As further described in Note 1, on February 2, 2023, the stockholders approved an amendment to our certificate of incorporation to consummate a business combination (unless we further extend the period of time to consummate a business combination) (the "Combination Period"). However, if the Company is unable to complete the initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company but net of taxes payable (and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining stockholders and the Company's board of directors, liquidate and dissolve, subject (in the case of (ii) and (iii) above) to the Company's obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

The Sponsor, officers and directors have agreed (i) to vote any shares owned by them in favor of any proposed Business Combination, (ii) not to redeem any shares in connection with a stockholder vote to approve a proposed initial Business Combination or sell any shares to the Company in a tender offer in connection with a proposed initial Business Combination, (iii) that the founders' shares will not participate in any liquidating distributions from the Company's Trust Account upon winding up if a Business Combination is not consummated.

The Sponsor has agreed that it will be liable to ensure that the proceeds in the Trust Account are not reduced below $10.00 per share by the claims of target businesses or claims of vendors or other entities that are owed money by the Company for services rendered or contracted for or products sold to the Company. The agreement to be entered into by the Sponsor will specifically provide for two exceptions to the indemnity it has given: it will have no liability (1) as to any claimed amounts owed to a target business or vendor or other entity who has executed an agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account, or (2) as to any claims for indemnification by the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has it independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Sponsor's only assets are securities of the Company. Therefore, the Company believes it is unlikely that the Sponsor will be able to satisfy its indemnification obligations if it is required to do so.

------

On December 17, 2021, the Company entered into a business combination agreement with Rezolve Limited, a private limited company incorporated under the laws of England and Wales ("<u>Rezolve</u>"), Rezolve Group Limited, a Cayman Islands exempted company ("<u>Cayman NewCo</u>"), and Rezolve Merger Sub, Inc., ("<u>Rezolve Merger Sub</u>") (such business combination agreement, the "<u>Business Combination Agreement</u>," and such business combination, the "<u>Business Combination</u>").

In connection with the execution of the definitive Business Combination Agreement, certain investors have agreed to purchase an aggregate of 2,050,000 ordinary shares of Cayman NewCo for the purchase price of $10.00 per share, for an aggregate purchase price of $20.5 million pursuant to certain subscription agreements (the "<u>Subscription Agreements</u>"). The obligations of each party under the subscription agreements are conditioned upon customary closing conditions and the consummation of the Business Combination.

Concurrently with the execution and delivery of the Business Combination Agreement, Armada and the Key Company Shareholders (as defined in the Business Combination Agreement) have entered into the Transaction Support Agreement (the "<u>Transaction Support Agreement</u>"), pursuant to which, among other things, the Key Company Shareholders have agreed to (a) vote in favor of the Company Reorganization (b) vote in favor of the Business Combination Agreement and the agreements contemplated thereby and the transactions contemplated thereby, (c) enter into the Investor Rights Agreement (as described below) at Closing and (d) the termination of certain agreements effective as of Closing.

On November 10, 2022, the Company and Rezolve entered into a First Amendment to the Business Combination Agreement (the "Amendment," and together with the Original Business Combination Agreement, the "Business Combination Agreement" and the business combination contemplated thereby, the "Business Combination"), to among other things, extend the date on which either party to the Business Combination Agreement had the right to terminate the Business Combination Agreement if the Business Combination had not been completed by such date to the later of (i) January 31, 2023 or (ii) fifteen days prior to the last date on which the Company may consummate a Business Combination, and change the structure of the Business Combination such that Cayman NewCo is no longer a party to the Business Combination Agreement or the Business Combination.

On February 2, 2023, the Company held an annual meeting of its stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders approved an amendment to the Company's Second Amended and Restated Certificate of Incorporation ("Charter") to extend the date by which the Company must consummate a business combination or, if it fails to do so, cease its operations and redeem or repurchase 100% of the shares of the Company's Common Stock issued in the Company's initial public offering, from February 17, 2023 for up to six additional months at the election of the Company, ultimately until as late as August 17, 2023 (the "Extension"). The Company filed an amendment to the Company's Charter with the Secretary of State of the State of Delaware reflecting the Extension. In connection with the Extension, the holders of 11,491,148 shares of Common Stock elected to redeem their shares at a per share redemption price of approximately $10.17 per February 2, 2023 filed Form 8-K. As a result, approximately $116,864,975 per February 2, 2023 filed Form 8-K will be removed from the Company's Trust Account to pay such holders.

Liquidity and Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.

As of December 31, 2022, the Company had approximately $0.4 million in its operating account and working capital deficiency of approximately $5 million (excluding income tax payable and franchise tax payable).

------

Prior to the completion of the IPO, the Company's liquidity needs have been satisfied through the $36,045 proceeds received from the sale of its Founder Shares to the Sponsor, the advances of $230,352 from the Sponsor to cover the Company's offering costs in connection with the IPO, and the net proceeds from the consummation of the Private Placement not held in the Trust Account. The balance of the advances from Sponsor was fully repaid on August 17, 2021.

On May 9, 2022, the Sponsor loaned the Company the aggregate amount of $483,034 in order to assist the Company to fund its working capital needs. On November 10, 2022 the Sponsor loaned the Company $1,500,000 in order to cover the additional contribution to the trust account in connection with the automatic extension and $450,000 to fund its working capital needs (see Note 3). These loans are evidenced by four promissory notes in the aggregate principal amount of $2,433,034 from the Company, as maker, to the Sponsor, as payee. The promissory notes are non-interest bearing and due on the earlier of: (i) the liquidation or release of all of the monies held in the Trust Account or (ii) the date on which the Company consummates an acquisition, merger or other business combination transaction involving the Company or its affiliates. The principal balance may be prepaid at any time. During July 2022, the Company fully repaid one of the promissory notes in the amount of $187,034 which represented monies loaned to the Company for the payment of Delaware franchise taxes. The Company utilized the interest earned on the Trust Account to repay the promissory note. The Company also paid $44,246 on behalf of the Sponsor for tax services in August and September 2022. The aggregate balance outstanding under all promissory notes was $2,201,754 and $251,754 of December 31, 2022 and September 30, 2022, respectively.

In order to finance transaction costs in connection with a Business Combination, the Company's Sponsor or an affiliate of the Sponsor or certain of the Company's officers and directors may, but are not obligated to, provide the Company with Working Capital Loans, as defined below (see Note 3). As of December 31, 2022, there were no amounts outstanding under any Working Capital Loans. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans.

In connection with the Company's assessment of going concern considerations in accordance with the Financial Accounting Standards Board's ("FASB") Accounting Standards Update ("ASU") 2014-15, "Disclosures of Uncertainties about an Entity's Ability to Continue as a Going Concern," management determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company's ability to continue as a going concern through August 17, 2023, the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These unaudited condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Risks and Uncertainties

Management is continuing to evaluate the impact of the COVID-19 pandemic on the industry, the geopolitical conditions resulting from the recent invasion of Ukraine by Russia and subsequent sanctions against Russia, Belarus and related individuals and entities and the status of debt and equity markets, as well as protectionist legislation in our target markets and has concluded that while it is reasonably possible that it could have a negative effect on the Company's financial position, results of its operations and/or that of Rezolve's or any other target company, the specific impact is not readily determinable as of the date of these unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.

On August 16, 2022, the Inflation Reduction Act of 2022 (the "IR Act") was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the "Treasury") has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.

------

Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of the Business Combination, (iii) the nature and amount of any "PIPE" or other equity issuances in connection with the Business Combination (or otherwise issued not in connection with the Business Combination but issued within the same taxable year of the Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company's ability to complete a Business Combination.

Note 2 — Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America ("GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by US GAAP. In the opinion of management, all adjustments (consisting of normal recurring adjustments) have been made that are necessary to present fairly the financial position, and the results of its operations and its cash flows for the period presented in the unaudited condensed financial statements. Operating results for the three months ended December 31, 2022, are not necessarily indicative of the results that may be expected through December 31, 2023.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company's Annual Report on Form10-K, as filed with SEC on December 13, 2022.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $363,247 and $177,578 in cash as of December 31, 2022 and September 30, 2022, respectively.

Investment Held in Trust Account

As of December 31, 2022 the assets held in the Trust Account were held in a money market fund. The Company's portfolio of investments held in the Trust Account is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, investments in money market funds that invest in U.S. government securities, cash, or a combination thereof. The Company's investments held in the Trust Account are classified as trading securities. Trading securities are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in gain on Investments Held in Trust Account in the accompanying condensed statement of operations.

------

As September 30, 2022, the assets held in the Trust Account were held in U.S. Treasury Bills with a maturity of 185 days or less and in money market funds which invest in U.S. Treasury securities.

The Company classifies its US Treasury bills as held-to-maturity in accordance with FASB ASC Topic 320 "Investments—Debt and Equity Securities." Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost and adjusted for the amortization or accretion of premiums or discounts.

A decline in the market value of held-to-maturity securities below cost that is deemed to be other than temporary, results in an impairment that reduces the carrying costs to such securities' fair value. The impairment is charged to earnings and a new cost basis for the security is established. To determine whether an impairment is other than temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. Evidence considered in this assessment includes the reasons for the impairment, the severity and the duration of the impairment, changes in value subsequent to year-end, forecasted performance of the investee, and the general market condition in the geographic area or industry in which the investee operates.

Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective-interest method. Such amortization and accretion are included in the "interest income" line item in the unaudited condensed statements of operations. Interest income is recognized when earned.

There were no held to maturity securities on December 31, 2022. The carrying value, excluding gross unrealized holding loss, and fair value of held to maturity securities on September 30, 2022 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Carrying<br> Value as of<br> September 30,<br> 2022 | Gross<br> Unrealized<br> Gains | Gross<br> Unrealized<br> Losses | Fair Value<br> as of<br> September 30,<br> 2022 |
| Cash | $320 | $— | $– $| 320 |
| U.S. Treasury Bills | 150844605 | 19242 | – | 150863847 |
|  | $150844925 | $19242 | $– $| 150864167 |

---

Held to maturity investments (U.S. Treasury Bills) recorded as of September 30, 2022 matured on October 22, 2022 and total amount of $151,046,320, including amortized interest, was reinvested in money market funds.

The estimated fair values of investments held in the Trust Account are determined using available market information and are characterized as Level 1 investments within the fair value hierarchy under ASC 820 (as described below).

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

• Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

------

• Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

• Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

The fair value of certain of the Company's assets and liabilities, which qualify as financial instruments under ASC 820, "Fair Value Measurements and Disclosures," approximates the carrying amounts represented in the condensed balance sheets.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation limit of $250,000. At December 31, 2022 and September 30, 2022, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Offering Costs Associated with IPO

The Company complies with the requirements of ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A—"Expenses of Offering". Offering costs consist of legal, accounting, underwriting and other costs incurred through the balance sheet date that are related to the IPO. The Company incurred offering costs amounting to $3,537,515 as a result of the IPO consisting of a $1,500,000 underwriting commissions, and $2,037,515 of other offering costs.

Common Stock Subject to Possible Redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 "Distinguishing Liabilities from Equity." Common stock subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company's control) are classified as temporary equity. At all other times, common stock are classified as stockholders' equity. The Company's shares of common stock feature certain redemption rights that are considered to be outside of the Company's control and subject to the occurrence of uncertain future events. Accordingly, 15,000,000 shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders' deficit section of the Company's condensed balance sheets.

The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the remeasurement adjustment from initial carrying amount to redemption book value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital.

------

At December 31, 2022 and September 30, 2022, the common stock reflected in the balance sheets are reconciled in the following table:

---

| | |
|:---|:---|
| Gross Proceeds | $150000000 |
| Less: Proceeds allocated to Public Warrants | (11700000) |
| Less: Issuance costs related to common stock | (3261589) |
| Plus: Remeasurement of carrying value to redemption value | 14961589 |
| Plus: Subsequent remeasurement of carrying value to redemption value – Trust interest income (excluding the amount that can be withdrawn from Trust Account) | 548862 |
| Common stock subject to possible redemption – September 30, 2022 | $150548862 |
| Plus: Remeasurement of carrying value to redemption value | 2479343 |
| Common stock subject to possible redemption – December 31, 2022 | $153028205 |

---

Net Income (Loss) Per Common Stock

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, "Earnings Per Share". Net income (loss) per common stock is computed by dividing net income (loss) by the weighted average number of common stock outstanding for the period. Remeasurement adjustments associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates fair value.

The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the IPO because the warrants are contingently exercisable, and the contingencies have not yet been met. The warrants are exercisable to purchase 7,500,000 shares of common stock in the aggregate. As of December 31, 2022 and 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net income (loss) per common stock is the same as basic net income (loss) per common stock for the periods presented.

Accretion of the carrying value of common stock subject to redemption value is excluded from net income (loss) per common stock because the redemption value approximates fair value.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Three months ended | Three months ended | Three months ended | Three months ended |
|  | December 31, 2022 | December 31, 2022 | December 31, 2021 | December 31, 2021 |
|  | Common stock<br> subject to<br> redemption | Common<br> stock | Common stock<br> subject to<br> redemption | Common stock |
| Basic and diluted net income (loss) per share |  |  |  |  |
| Numerator: |  |  |  |  |
| Allocation of net income (loss) | $439673 | $167354 | $(1474768) | $(561346) |
| Denominator |  |  |  |  |
| Weighted-average shares outstanding | 15000000 | 5709500 | 15000000 | 5709500 |
| Basic and diluted net income (loss) per share | $0.03 | $0.03 | $(0.10) | $(0.10) |

---

Stock Based Compensation

The Company accounts for share-based payments in accordance with FASB ASC Topic 718, "Compensation–- Stock Compensation," ("ASC 718") which requires that all equity awards be accounted for at their "fair value." The Company measures and recognizes compensation expense for all share-based payments on their estimated fair values measured as of the grant date. These costs are recognized as an expense in the condensed statements of operations upon vesting, once the applicable performance conditions are met, with an offsetting increase to additional paid-in capital. Forfeitures are recognized as they occur.

------

On June 16, 2021, the Sponsor transferred 50,000 shares to each of its Chief Executive Officer and to its President and 35,000 shares to each of its three independent directors. The aforementioned transfer is in the scope of ASC 718. Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The aggregate fair value of these shares was $509,552 at issuance. A total of 100,000 shares vested upon consummation of the Initial Public Offering. The remaining 105,000 shares vest in equal quarterly installments until the second anniversary of the consummation of the Company's Initial Public Offering, or August 17, 2023. For each of the three months ended December 31, 2022 and 2021 the Company recognized $27,963 of stock based compensation.

At December 31, 2022 there are 33,750 shares that remain unvested. Total unrecognized compensation expense related to the unvested shares at December 31, 2022 amounted to $83,891 and is expected to be recognized over a period of 0.6 years.

Income Taxes

The Company accounts for income taxes under ASC 740, "Income Taxes." ASC 740, Income Taxes, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and September 30, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

The Company has identified the United States as its only "major" tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company's management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

As of December 31, 2022 and September 30, 2022, the Company's deferred tax asset had a full valuation allowance recorded against it. Our effective tax rate was (30.01)% for three months ended December 30, 2022, and 0.00% for the three months ended December 31, 2021. The effective tax rate differs from the statutory tax rate of 21% for three months ended December 30, 2022 and 2021, due to the valuation allowance on the deferred tax assets.

------

Management does not believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company's condensed financial statements.

Note 3 — Related Party Transactions

Promissory Notes-Related Party

On May 9, 2022, the Sponsor loaned the Company the aggregate amount of $483,034 in order to assist the Company to fund its working capital needs. The loan is evidenced by two promissory notes in the aggregate principal amount of $483,034 from the Company, as maker, to the Sponsor, as payee. On November 10, 2022 the Sponsor loaned the Company $1,500,000 in order to cover the additional contribution to the trust account in connection with the automatic extension and $450,000 to fund its working capital needs. The promissory notes are non-interest bearing and due on the earlier of: (i) the liquidation or release of all of the monies held in the Trust Account or (ii) the date on which the Company consummates an acquisition, merger or other business combination transaction involving the Company or its affiliates. The principal balance may be prepaid at any time.

During July 2022, the Company fully repaid one of the promissory notes in the amount of $187,034 which represented monies loaned to the Company for the payment of Delaware franchise taxes. The Company utilized the interest earned on the Trust Account to repay the promissory note. The Company also paid $44,246 on behalf of the Sponsor for tax services in August and September 2022. The aggregate balance outstanding under all promissory notes was $2,201,754 and $251,754 of December 31, 2022 and September 30, 2022, respectively.

Working Capital Loans

In order to meet the Company's working capital needs following the consummation of the IPO, the Sponsor, officers, directors or their affiliates may, but are not obligated to, loan the Company funds ("Working Capital Loans"), from time to time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be non-interest bearing and be evidenced by a promissory note. The notes would either be paid upon consummation of the initial Business Combination, without interest, or, at holder's discretion, up to $1,500,000 of the notes may be converted into shares at a price of $10.00 per share. The shares would be identical to the Private Shares. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from the Trust Account would be used for such repayment. As of December 31, 2022 and September 30, 2022, no such Working Capital Loans were outstanding.

Administrative Service Fee

Commencing on the date of the IPO, the Company will pay the Sponsor $10,000 per month for office space, utilities and secretarial support. Upon completion of the initial Business Combination or the Company's liquidation, the Company will cease paying these monthly fees. For each of the three months ended December 31, 2022 and 2021, the Company incurred and paid $30,000 in administrative service fees.

Note 4 — Commitments & Contingencies

Registration Rights

The holders of the Founder Shares issued and outstanding on the date of the IPO, as well as the holders of the representative shares, Private Shares and any shares the Company's Sponsor, officers, directors or their affiliates may issue in payment of Working Capital Loans made to the Company, will be entitled to registration rights pursuant to an agreement to be signed prior to or on the effective date of the IPO. The holders of a majority of these securities (other than the holders of the representative shares) are entitled to make up to two demands that

------

the Company registers such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Shares and shares issued to the Company's Sponsor, officers, directors or their affiliates in payment of Working Capital Loans made to the Company can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain "piggy-back" registration rights with respect to registration statements filed subsequent to the Company's consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters were paid a cash underwriting discount of 1.0% of the gross proceeds of the IPO, or $1,500,000 (and are entitled to an additional $225,000 of deferred underwriting commission payable at the time of an initial Business Combination if the underwriters' over-allotment is exercised in full). On October 1, 2021 the underwriters' over-allotment option expired unused resulting in the $225,000 deferred underwriting commission to be not payable to the underwriter.

Financial Advisory Fee

The Company engaged Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC ("CCM"), an affiliate of a member of the Sponsor, to provide consulting and advisory services in connection with the IPO, for which it received an advisory fee equal to one (1.0) percent of the aggregate proceeds of the IPO, or $1,500,000, upon closing of the IPO. Affiliates of CCM have and manage investment vehicles with a passive investment in the Sponsor. On August 18, 2021, the Company paid to CCM in aggregate of $1,500,000. CCM has agreed to defer the payment of the portion of the advisory fee attributable to over-allotment option until the consummation of the initial Business Combination. CCM is engaged to represent the Company's interests only. The Company will also engage CCM as an advisor in connection with the initial Business Combination for which it will earn an advisory fee of 2.25% of the gross proceeds of the IPO, or $3,375,000, payable at closing of the Business Combination. On October 1, 2021 the underwriters' over-allotment option expired unused resulting in no additional fees and commissions related to the over-allotment option to be not payable to CCM by the Company.

Business Combination Marketing Agreement

The Company engaged the representative of the underwriter as an advisor in connection with Business Combination to assist in holding meetings with the Company's stockholders to discuss the potential Business Combination and the target business' attributes, introduce the Company to potential investors that are interested in purchasing the Company's securities in connection with the initial Business Combination and assist the Company with press releases and public filings in connection with the Business Combination. The Company will pay the representative a cash fee for such services upon the consummation of the initial Business Combination in an amount equal to 2.25% of the gross proceeds of the IPO, or $3,375,000. The Company will also pay the representative a separate capital market advisory fee of $2,500,000 upon completion of the initial Business Combination. Additionally, the Company will pay the representative a cash fee equal to 1.0% of the total consideration payable in the proposed Business Combination if the representative introduces the Company to the target business with which the Company completes a Business Combination. On October 1,2021the underwriters' over-allotment option expired unused resulting in no additional marketing fees related to the over-allotment option to be not payable to the representative on the underwriter by the Company.

On November 10, 2022, the Company and Rezolve entered into a First Amendment to the Business Combination Agreement (the "Amendment," and together with the Original Business Combination Agreement, the "Business Combination Agreement" and the business combination contemplated thereby, the "Business Combination"), to among other things, extend the date on which either party to the Business Combination Agreement had the right to terminate the Business Combination Agreement if the Business Combination had not been completed by such date to the later of (i) January 31, 2023 or (ii) fifteen days prior to the last date on which the Company may consummate a Business Combination, and change the structure of the Business Combination such that Cayman NewCo is no longer a party to the Business Combination Agreement or the Business Combination.

------

Right of First Refusal

If the Company determines to pursue any equity, equity-linked, debt or mezzanine financing relating to or in connection with an initial Business Combination, then Northland Securities, Inc. shall have the right, but not the obligation, to act as book running manager, placement agent and/or arranger, as the case may be, in any and all such financing or financings. This right of first refusal extends from the date of the IPO until the earlier of the consummation of an initial Business Combination or the liquidation of the Trust Account if the Company fails to consummate a Business Combination during the required time period.

Note 5 — Recurring Fair Value Measurements

As of December 31, 2022 , the assets held in the Trust Account were held in money market funds which invest in U.S. Treasury securities. As of September 30, 2022, the assets held in the Trust Account were held in U.S. Treasury Bills with a maturity of 185 days or less. .

There were no transfers between Levels 1, 2 or 3 during the three months ended December 31, 2022 and 2021.

Note 6 — Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, other than as disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in these unaudited condensed financial statements.

On January 20, 2023, the Company and its Sponsor, entered into one or more agreements (the "Non-Redemption Agreements") with one or more third parties in exchange for them agreeing not to redeem shares of the Company's common stock sold in its Initial Public Offering (the "public shares") at the 2023 annual meeting of stockholders called by the Company (the "Meeting") at which a proposal to approve an extension of time for the Company to consummate an initial business combination (the "Extension Proposal") from February 17, 2023 to August 17, 2023 (the "Extension") has also been submitted to the stockholders. The Non-Redemption Agreements provide for the allocation of up to 75,000 shares of common stock of the Company ("Founder Shares") held by the Sponsor in exchange for such investor and/or investors agreeing to hold and not redeem certain public shares at the Meeting. Certain of the parties to the Non-Redemption Agreements are also members of the Sponsor.

The Non-Redemption Agreements shall terminate on the earlier of (a) the failure of the Company's stockholders to approve the Extension at the Meeting, or the determination of the Company not to proceed to effect the Extension, (b) the fulfillment of all obligations of parties to the Non-Redemption Agreements, (c) the liquidation or dissolution of the Company, or (d) the mutual written agreement of the parties. Additionally, pursuant to the Non-Redemption Agreements, the Company has agreed that until the earlier of (a) the consummation of the Company's initial business combination; (b) the liquidation of the trust account; and (c) 24 months from consummation of the Company's initial public offering, the Company will maintain the investment of funds held in the trust account in interest-bearing United States government securities within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended, having a maturity of 185 days or less, or in money market funds meeting the conditions of paragraphs (d)(1), (d)(2), (d)(3) and (d)(4) of Rule 2a-7 promulgated under the Investment Company Act of 1940, as amended, which invest only in direct U.S. government treasury obligations. The Company has also agreed that it will not use any amounts in the trust account, or the interest earned thereon, to pay any excise tax that may be imposed on the Company pursuant to the Inflation Reduction Act (IRA) of 2022 (H.R. 5376) due to any redemptions of public shares at the Meeting, including in connection with a liquidation of the Company if it does not effect a business combination prior to its termination date by the Company. The Non-Redemption Agreements are not expected to increase the likelihood that the Extension Proposal is approved by stockholders but will increase the amount of funds that remain in the Company's trust account following the Meeting.

On February 2, 2023, the Company held an annual meeting of its stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders approved an amendment to the Company's Charter to extend the date by which the Company must consummate a business combination or, if it fails to do so, cease its operations and redeem or repurchase 100% of the shares of the Company's Common Stock issued in the Company's initial public offering, from February 17, 2023 for up to six additional months at the election of the Company,

------

ultimately until as late as August 17, 2023 (the "Extension"). The Company filed an amendment to the Company's Charter with the Secretary of State of the State of Delaware reflecting the Extension. In connection with the Extension, the holders of 11,491,148 shares of Common Stock elected to redeem their shares at a per share redemption price of approximately $10.17 per Feb 2, 2023 filed Form 8-K. As a result, approximately $116,864,975 per Feb 2, 2023 filed Form 8-K will be removed from the Company's Trust Account to pay such holders.

------

##### [**Table of Contents**](#toc)

#### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
*The following discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this report. References to the "Company," "us" or "we" refer to Armada Acquisition Corp. I.* 

#### Cautionary Note Regarding Forward-Looking Statements
*This Quarterly Report on Form10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "continue," or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission ("SEC") filings.* 

On February 2, 2023, we held an annual meeting of our stockholders (the "Annual Meeting"). At the Annual Meeting, our stockholders approved an amendment to the Company's Charter to extend the date by which the Company must consummate a business combination or, if it fails to do so, cease its operations and redeem or repurchase 100% of the shares of the Company's Common Stock issued in the Company's initial public offering, from February 17, 2023 for up to six additional months at the election of the Company, ultimately until as late as August 17, 2023 (the "Extension"). We filed an amendment to the Company's Charter with the Secretary of State of the State of Delaware reflecting the Extension. In connection with the Extension, the holders of 11,491,148 shares of Common Stock elected to redeem their shares at a per share redemption price of approximately $10.19. As a result, we will remove approximately $117,079,879 from our Trust Account to pay such holders.

We are a blank check company incorporated in Delaware on November 5, 2020, for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses.

On August 17, 2021, we consummated our IPO of 15,000,000 units, at $10.00 per unit, generating gross proceeds of $150 million.

Simultaneously with the closing of the IPO, we consummated the private placement of 459,500 Private Shares for an aggregate purchase price of $4,595,000.

Upon the closing of the IPO on August 17, 2021, $150,000,000 ($10.00 per unit) from the net proceeds of the sale of the units in the IPO and the sale of Private Shares were placed in the Trust Account.

If we are unable to complete the initial Business Combination within the Combination Period, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us but net of taxes payable (and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, liquidate and dissolve, subject (in the case of (ii) and (iii) above) to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

On February 2, 2023, we held an annual meeting of our stockholders (the "Annual Meeting"). At the Annual Meeting, our stockholders approved an amendment to the Company's Charter to extend the date by which the Company must consummate a business combination or, if it fails to do so, cease its operations and redeem or repurchase 100% of the shares of the Company's Common Stock issued in the Company's initial public offering, from February 17, 2023 for up to six additional months at the election of the Company, ultimately until as late as August 17, 2023 (the "Extension"). We filed an amendment to the Company's Charter with the Secretary of State of the State of Delaware reflecting the Extension. In connection with the Extension, the holders of 11,491,148 shares of Common Stock elected to redeem their shares at a per share redemption price of approximately $10.17 per Feb 2, 2023 filed Form 8-K. As a result, we will remove approximately $116,864,975 per Feb 2, 2023 filed Form 8-K from our Trust Account to pay such holders.

------

##### [**Table of Contents**](#toc)

#### Business Combination Agreement
On December 17, 2021, we announced that we entered into a business combination agreement, dated as of December 17, 2021, with Rezolve Limited, a private limited liability company registered under the laws of England and Wales ("<u>Rezolve</u>"), Rezolve Group Limited, a Cayman Islands exempted company ("Cayman NewCo"), and Rezolve Merger Sub, Inc., a Delaware corporation ("<u>Rezolve</u> <u>Merger Sub</u>") (such business combination agreement, the "<u>Business Combination Agreement</u>," and such business combination, the "<u>Business Combination</u>").

Pursuant to the terms of the Business Combination Agreement, we, Cayman NewCo, Rezolve and Rezolve Merger Sub will effect a series of transactions including, among other things:

• a company reorganization pursuant to which Cayman NewCo will enter into a transfer and exchange agreement (the "Transfer and Exchange Agreement"), pursuant to which, each Key Company Shareholder (as defined in the Business Combination Agreement) will transfer to Cayman NewCo his, her or its respective shares of Rezolve in exchange for ordinary shares in Cayman NewCo, such that following the effectiveness of such transfers, the Key Company Shareholders will own the same proportionate equity interests of Cayman NewCo that such Key Company Shareholders owned immediately before such transfers (with the balance of the other shares of Rezolve to be transferred to Cayman NewCo in exchange for an equivalent number and class of shares in Cayman NewCo) and, immediately thereafter, each Key Company Shareholder will transfer to Cayman NewCo all of his, her or its respective shares of Cayman NewCo so received in exchange for his, her or its applicable pro rata portion of the aggregate stock consideration in accordance with the terms and conditions set forth in the Business Combination Agreement and in such Transfer and Exchange Agreement (with all other shareholders of Rezolve to transfer to Cayman NewCo all of his, her or its respective shares of Cayman NewCo received in exchange for his, her or its applicable pro rata portion of the aggregate stock consideration); and

• following the Company Reorganization, but in no event earlier than ten (10) days following the effectiveness of each of the transactions contemplated by the Company Reorganization: (a) Rezolve Merger Sub shall be merged with and into Armada whereupon Rezolve Merger Sub will cease to exist and with Armada surviving the Merger as a subsidiary of Cayman NewCo; and (b) Armada shall loan all of its remaining cash in the Trust Account to Cayman NewCo in exchange for a promissory note, to enable Cayman NewCo to fund working capital and transaction expenses. Pursuant to the Merger, all of the outstanding securities of Armada will be converted into the right to receive an equivalent number of securities of Cayman NewCo of the same type and with the same terms.

As a result of the Business Combination (i) the shareholders of Rezolve will receive a number of Cayman NewCo ordinary shares equal to (A) the quotient obtained by dividing (x) $1,750,000,000 by (y) $10.00 minus (B) the Outstanding Warrant Number (as defined in the Business Combination Agreement) and minus (C) the Acquisition Shares (as defined in the Business Combination Agreement) (to the extent such Acquisition Shares are not already issued on or prior to the Company Reorganization Date), and (ii) the combined company will pay or cause to be paid all of the transaction expenses.

The consummation of the Business Combination is subject to the satisfaction or waiver of certain customary closing conditions of the respective parties, including the completion of the Company Reorganization, the requisite approvals of our stockholders and Rezolve's shareholders and regulatory approvals.

In connection with the execution of the Business Combination Agreement, we and Cayman NewCo entered into certain subscription agreements, each dated December 17, 2021 (the "<u>Subscription Agreements</u>"), with certain investors, pursuant to which such investors have agreed to purchase an aggregate of 2,050,000 Ordinary Shares (the "<u>PIPE Shares</u>") of Cayman NewCo (together, the "<u>Subscriptions</u>"), for a purchase price of $10.00 per share, for an aggregate purchase price of $20.5 million to be issued substantially concurrently with the consummation of the Business Combination. The obligations of each party to consummate the Subscriptions are conditioned upon, among other things, customary closing conditions.

------

##### [**Table of Contents**](#toc)
On November 10, 2022 (the "<u>Amendment Date</u>"), Armada and Rezolve entered into a First Amendment to the Business Combination Agreement (the "<u>Amendment</u>"). Except as specifically set forth in the Amendment, all other terms and provisions of the original Business Combination Agreement remain unaffected and continue in full force and effect. Below is a summary of the key amendments:

*Structure of the Business Combination* 

The Amendment amends the Business Combination Agreement so that Rezolve is substituted for Cayman Newco as applicable. As a result of this amendment, Cayman Newco is no longer a party to the Business Combination Agreement or the Business Combination, and Rezolve will be the listed entity upon the closing. As necessary, Armada and Rezolve have agreed to make any amendments to the Ancillary Documents as are necessary or appropriate to effect the substitution of Rezolve for Cayman Newco in the Business Combination.

*Termination* 

The original Business Combination Agreement allowed the parties to terminate such agreement if certain conditions described therein are satisfied. One such condition allowed either Armada or Rezolve to terminate the Business Combination Agreement if the Business Combination is not consummated by August 31, 2022 (the "<u>Termination Date</u>"). The Amendment extended the Termination Date to the later of (i) January 31, 2023 or (ii) fifteen (15) days prior to the last date on which Armada may consummate a Business Combination, as defined in and pursuant to the Second Amended and Restated Certificate of Incorporation of Armada, as approved or extended by the stockholders of Armada from time to time.

The original Business Combination Agreement allowed either Armada or Rezolve to terminate the Business Combination Agreement in the event the aggregate transaction proceeds provided or committed to be provided are not more than fifty million dollars ($50,000,000). The Amendment deleted this provision in its entirety.

*Incentive Plan* 

Under the Amendment, Armada and Rezolve agreed and acknowledged that following June 30, 2023, the Board has the right to increase the number of Rezolve shares under the Rezolve Incentive Plan by up to 5% per annum for each calendar year commencing in and including 2023, subject to appropriate shareholder approval as required by applicable law or the NASDAQ rules and regulations.

*Articles of Association* 

Pursuant to the Amendment, Armada and Rezolve agreed upon the form of the articles of association of Rezolve to be adopted and become effective upon closing of the Business Combination.

We cannot assure you that our plans to complete our initial business combination will be successful.

#### Results of Operations
For the three months ended December 31, 2022, we had a net income of $607,027, which consisted of trust interest income of $1,289,673, offset by formation and operating costs of $394,352, stock-based compensation of $27,963, and income tax provision of $260,331.

For the three months ended December 31, 2021, we had a net loss of $2,036,114, which consisted of operating costs and costs related to a prospective initial Business Combination of $2,010,995 and stock-based compensation of $27,963, partially offset by trust interest income of $2,844.

Following the exercise of the automatic extension of the deadline for us to complete an initial business combination under our second amended and restated certificate of incorporation ("Charter"), we had until February 17, 2023 (or 18 months following our initial public offering) to consummate a business combination (unless we further extend the period of time to consummate a business

------

##### [**Table of Contents**](#toc)
combination) (the "<u>Combination Period</u>"). At our Annual Meeting held on February 2, 2023, our stockholders approved an amendment to our Charter to consummate a business combination (unless we further extend the period of time to consummate a business combination) (the "Combination Period"). However, if we are unable to complete the initial Business Combination within the Combination Period (unless such period is further extended pursuant to the approval of our stockholders), we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company but net of taxes payable (and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and the Company's board of directors, liquidate and dissolve, subject (in the case of (ii) and (iii) above) to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. As of December 31, 2022 the Trust Account has released $182,069 to the Company to pay tax obligations.

We have also agreed to reimburse the Sponsor for office space, secretarial and administrative services provided to members of our management team, in an amount not to exceed $10,000 per month. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees. For the three months ended December 31, 2022 and 2021, the Company paid $30,000 under this agreement

#### Liquidity and Going Concern
As of December 31, 2022, we had cash outside our Trust Account of $363,247, available for working capital needs. All remaining cash was held in the Trust Account and is generally unavailable for our use, prior to an initial business combination.

On August 17, 2021, we completed the sale of 15,000,000 Units at $10.00 per Unit, generating gross proceeds of $150,000,000.

Simultaneously with the consummation of the IPO, the Company consummated the private placement of 459,500 shares of common stock ("<u>Private Shares</u>"), at a price of $10.00 per share for an aggregate purchase price of $4,595,000.

In connection with the IPO, the underwriters were granted a 45-day option from the date of the prospectus for the IPO to purchase up to 2,250,000 additional units to cover over-allotments, if any. On October 1, 2021 this option expired unused.

Following our IPO and the sale of the Private Shares, a total of $150,000,000 ($10.00 per Unit) was placed in the Trust Account. We incurred $3,537,515 in IPO related costs, including $1,500,000 of underwriting fees and $2,037,515 of other costs.

On May 9, 2022, the Sponsor loaned us the aggregate amount of $483,034 in order to assist us to fund our working capital needs. On November 10, 2022 our Sponsor loaned us $1,500,000 in order to cover the additional contribution to the trust account required in connection with the automatic extension of our deadline to complete our Initial Business Combination and $450,000 for our working capital needs. These loans are evidenced by four promissory notes in the aggregate principal amount of $2,433,034 from us, as maker, to our Sponsor, as payee. The promissory notes are non-interest bearing and due on the earlier of: (i) the liquidation or release of all of the monies held in the Trust Account or (ii) the date on which we consummate an acquisition, merger or other business combination transaction involving us or our affiliates. The principal balance may be prepaid at any time. During July 2022, we fully repaid one of the promissory notes in the amount of $187,034 which represented monies loaned to us for the payment of Delaware franchise taxes. We utilized the interest earned on the Trust Account to repay the promissory note, $120,000 of which was distributed to it from the Trust Account during June 2022, and $62,069 of which was distributed to it from the Trust Account during July 2022. We also paid $44,246 on behalf of the Sponsor for tax services in August and September 2022.The aggregate balance outstanding under all promissory notes was $2,201,754 and $251,754 of December 31, 2022 and September 30, 2022, respectively.

As of December 31, 2022, we had investment held in the Trust Account of $153,634,598. The investment held in the Trust Account was held in U.S. Treasury Bills with a maturity of 185 days or less and in money market funds which invest in U.S. Treasury securities. Interest income on the balance in the Trust Account may be used by us to pay taxes.

------

##### [**Table of Contents**](#toc)
As of December 31, 2022, the Trust Account has released $182,069 to the Company to pay franchise tax obligations. In connection with the Extension approved by our stockholders on February 2, 2023, the holders of 11,491,148 shares of Common Stock elected to redeem their shares at a per share redemption price of approximately $10.17. As a result, approximately $116,864,975 will be removed from the Company's Trust Account to pay such holders. For the three months ended December 31, 2022, cash used in operating activities was $264,331. Net income of $607,027 was impacted primarily by trust interest income of $1,289,673, changes in operating assets and liabilities of $390,352 and stock-based compensation of $27,963.

For the three months ended December 31, 2021, cash used in operating activities was $237,890. Net loss of $2,036,114 was impacted primarily by changes in operating assets and liabilities of $1,773,105, stock-based compensation of $27,963, and trust interest income of $2,844.

We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account to complete our initial business combination. We may withdraw interest to pay our taxes and liquidation expenses if we are unsuccessful in completing a business combination. We estimate our annual franchise tax obligations to be $200,000, which is the maximum amount of annual franchise taxes payable by us as a Delaware corporation per annum, which we may pay from funds from the Public Offering held outside of the Trust Account or from interest earned on the funds held in the Trust Account and released to us for this purpose. Our 2021 Delaware franchise tax amounted to $182,069. Our annual income tax obligations will depend on the amount of interest and other income earned on the amounts held in the Trust Account reduced by our operating expense and franchise taxes. We expect the interest earned on the amount in the Trust Account will be sufficient to pay our income taxes. To the extent that our equity or debt is used, in whole or in part, as consideration to complete our initial business combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies. As of December 31, 2022 the Trust Account has released $182,069 to the Company to pay tax obligations.

Further, our sponsor, officers and directors or their respective affiliates may, but are not obligated to, loan us funds as may be required. If we complete a business combination, we would repay the loans. In the event that a business combination does not close, we may use a portion of proceeds held outside the Trust Account to repay the loans, but no proceeds held in the Trust Account would be used to repay the loans. Such loans would be evidenced by promissory notes and would be repaid upon consummation of a business combination, without interest. As of December 31, 2022, there was a balance due to the Sponsor of $2,201,754 under the loans.

On November 10, 2022, our Sponsor loaned us $1.5 million in order to cover the additional contribution to the trust account required in connection with the automatic extension of the deadline to complete our initial business combination and $0.45 million dollars for working capital purposes. However, if our estimates of the operating costs are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our business combination. Under the original Business Combination Agreement, either we or Rezolve could have terminated the Business Combination Agreement if the aggregate transaction proceeds (excluding certain amounts invested by the investors specified in the Business Combination Agreement) provided or committed to be provided was not more than $50 million. The Amendment entered into in November 2022 eliminated this provision in its entirety. If we are unable to complete a business combination (including the Business Combination) because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Account.

In connection with our assessment of going concern considerations in accordance with FASB Accounting Standards Update ("ASU") 2014-15, "Disclosures of Uncertainties about an Entity's Ability to Continue as a Going Concern," our management has determined that we have and will continue to incur significant costs in pursuit of acquisition plans which, in addition to possibility that we might not be able to a close business combination and be forced to liquidate after August 17, 2023 raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities that might be necessary if we are unable to continue as a going concern.

------

##### [**Table of Contents**](#toc)

#### Critical Accounting Policies
The preparation of these unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. We have identified the following as our critical accounting policies:

#### Common Stock Subject to Possible Redemption
The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 "Distinguishing Liabilities from Equity." Common stock subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company's control) are classified as temporary equity. At all other times, common stock are classified as stockholders' equity. The Company's shares of common stock feature certain redemption rights that are considered to be outside of the Company's control and subject to the occurrence of uncertain future events. Accordingly, 15,000,000 shares of common stock subject to possible redemption are presented at redemption value as temporary equity, outside of the stockholders' equity section of the Company's condensed balance sheets.

The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the remeasurement adjustment from initial carrying amount to redemption book value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital.

#### Net Income (Loss) Per Common Stock
The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, "Earnings Per Share". Net income (loss) per common stock is computed by dividing net loss by the weighted average number of common stock outstanding for the period. Remeasurement adjustments associated with the redeemable shares of common stock is excluded from earnings per share as the redemption value approximates fair value.

The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the IPO because the warrants are contingently exercisable, and the contingencies have not yet been met. The warrants are exercisable to purchase 7,500,000 shares of common stock in the aggregate. As of December 31, 2022 and 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted net income (loss) per common stock is the same as basic net income (loss) per common stock for the periods presented.

Accretion of the carrying value of common stock subject to redemption value is excluded from net income (loss) per common stock because the redemption value approximates fair value.

#### Recent Accounting Standards
Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company's financial statements.

#### Off-Balance Sheet Arrangements; Commitments and Contractual Obligations
We have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.

We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or entered into any non-financial agreements involving assets.

------

##### [**Table of Contents**](#toc)

#### Contractual Obligations
We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities other than an administrative agreement to reimburse our sponsor for office space, secretarial and administrative services not to exceed $10,000 per month from the date of closing of the Public Offering. Upon completion of a business combination or the Company's liquidation, the Company will cease paying these monthly fees.

*Financial Advisory Fee* 

We engaged Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC ("<u>CCM</u>"), an affiliate of a member of the Sponsor, to provide consulting and advisory services in connection with the IPO, for which it received an advisory fee equal to one (1.0) percent of the aggregate proceeds of the IPO, or $1,500,000, upon closing of the IPO. Affiliates of CCM have and manage investment vehicles with a passive investment in the Sponsor. On August 18, 2021, we paid to CCM an aggregate of $1,500,000. CCM has agreed to defer the payment of the portion of the advisory fee attributable to over-allotment option until the consummation of the initial Business Combination. CCM is engaged to represent our interests only. We have also engaged CCM as an advisor in connection with the initial Business Combination for which it will earn an advisory fee of 2.25% of the gross proceeds of the IPO, or $3,375,000, payable at closing of the Business Combination. On October 1, 2021 the underwriters' over-allotment option expired unused resulting in no additional fees and commissions related to the over-allotment option to be not payable to CCM by the Company.

*Business Combination Marketing Agreement* 

We engaged the representative of the underwriter as an advisor in connection with Business Combination to assist in holding meetings with our stockholders to discuss the potential Business Combination and the target business' attributes, introduce us to potential investors that are interested in purchasing our securities in connection with the initial Business Combination and assist us with press releases and public filings in connection with the Business Combination. We will pay the representative a cash fee for such services upon the consummation of the initial Business Combination in an amount equal to 2.25% of the gross proceeds of the IPO, or $3,375,000. We will also pay the representative a separate capital market advisory fee of $2,500,000 upon completion of the initial Business Combination. Additionally, we will pay the representative a cash fee equal to 1.0% of the total consideration payable in the proposed Business Combination if the representative introduces us to the target business with which the Company completes a Business Combination.

*Right of First Refusal* 

If we determine to pursue any equity, equity-linked, debt or mezzanine financing relating to or in connection with an initial Business Combination, then Northland Securities, Inc. shall have the right, but not the obligation, to act as book running manager, placement agent and/or arranger, as the case may be, in any and all such financing or financings.

This right of first refusal extends from the date of the IPO until the earlier of the consummation of an initial Business Combination or the liquidation of the Trust Account if the Company fails to consummate a Business Combination during the required time period.

*Registration Rights* 

The holders of the Founder Shares issued and outstanding on the date of the IPO, as well as the holders of the representative shares, Private Shares and any shares the sponsor, officers, directors or their affiliates may issue in payment of Working Capital Loans made to us, will be entitled to registration rights pursuant to an agreement to be signed prior to or on the effective date of the IPO. The holders of a majority of these securities (other than the holders of the representative shares) are entitled to make up to two demands that we register such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Shares and shares issued to the Sponsor, officers, directors or their affiliates in payment

------

##### [**Table of Contents**](#toc)
of Working Capital Loans made to us can elect to exercise these registration rights at any time after we consummate a business combination. In addition, the holders have certain "piggy-back" registration rights with respect to registration statements filed subsequent to the consummation of a business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

*Underwriting Agreement* 

The underwriters were paid a cash underwriting discount of 1.0% of the gross proceeds of the IPO, or $1,500,000 (and are entitled to an additional $225,000 of deferred underwriting commission payable at the time of an initial Business Combination if the underwriters' over-allotment is exercised in full). On October 1, 2021 the underwriters' over-allotment option expired unused resulting in the $225,000 deferred underwriting commission to be not payable to the underwriter.

*Business Combination Agreement* 

We are party to the Business Combination Agreement with Rezolve, Cayman NewCo and Rezolve Merger Sub, dated December 17, 2021. Completion of the proposed transaction pursuant to the Business Combination Agreement is subject to customary closing conditions, including the approval of the Company's and Rezolve's respective stockholders and regulatory approvals.

In connection with the execution of the Business Combination Agreement, certain investors have agreed to purchase an aggregate of 2,050,000 ordinary shares of Cayman NewCo for the purchase price of $10.00 per share, for an aggregate purchase price of $20.5 million pursuant to certain subscription agreements (the "<u>Subscription Agreements</u>"). The obligations of each party under the subscription agreements are conditioned upon customary closing conditions and the consummation of the Business Combination.

On November 10, 2022, Armada and Rezolve entered into a First Amendment to the Business Combination Agreement (the "<u>Amendment</u>"), to among other things, extend the date on which either party to the Business Combination Agreement had the right to terminate the Business Combination Agreement if the Business Combination had not been completed by such date, and change the structure of the Business Combination such that Cayman NewCo is no longer a party to the Business Combination Agreement or the Business Combination.

Concurrently with the execution and delivery of the Business Combination Agreement, the Company and the Key Company Shareholders (as defined in the Business Combination Agreement) have entered into the Transaction Support Agreement (the "<u>Transaction Support Agreement</u>"), pursuant to which, among other things, the Key Company Shareholders have agreed to (a) vote in favor of the Company Reorganization (b) vote in favor of the Business Combination Agreement and the agreements contemplated thereby and the transactions contemplated thereby, (c) enter into the Investor Rights Agreement (as described below) at Closing and (d) the termination of certain agreements effective as of Closing.

#### Item 3. Quantitative and Qualitative Disclosures About Market Risk
Following the consummation of our IPO on August 17, 2021, after releasing funds to Armada to be held outside of the Trust, $150,000,000 from the net proceeds of the sale of the units in the IPO was held in a Trust Account and has been invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the "Investment Company Act"), having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

------

##### [**Table of Contents**](#toc)

#### Item 4. Controls and Procedures

#### Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2022, as such term is defined in Rules 13a-15(e)and15d-15(e)under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that as of December 31, 2022, our disclosure controls and procedures were effective.

#### Changes in Internal Control over Financial Reporting
There were no changes to our internal control over financial reporting that occurred during our fiscal quarter ended December 31, 2022, that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

------

##### [**Table of Contents**](#toc)

#### PART II—OTHER INFORMATION

#### Item 1. Legal Proceedings.
None.

#### Item 1A. Risk Factors.
Except as set forth below, as of the date of this Quarterly Report, there have been no material changes with respect to those risk factors previously disclosed in our Annual Report on Form10-K for the year ended September 30, 2022, as filed with SEC on December 13, 2022. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

***We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, an ongoing military conflict between Russia and Ukraine, and record inflation. Our business, financial condition and results of operations could be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine, geopolitical tensions, or record inflation.***

U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. In February 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has contributed to record inflation globally. We are continuing to monitor inflation, the situation in Ukraine and global capital markets and assessing its potential impact on our business.

Although, to date, our business has not been materially impacted by the ongoing military conflict between Russian and Ukraine, geopolitical tensions, or record inflation, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which such matters may impact our business. The extent and duration of the conflict in Ukraine, geopolitical tensions, record inflation and resulting market disruptions are impossible to predict but could be substantial. Any such disruptions may also magnify the impact of other risks described in our Annual Report.

#### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.

#### Item 3. Defaults Upon Senior Securities.
None.

#### Item 4. Mine Safety Disclosures.
Not Applicable.

#### Item 5. Other Information.
None.

#### Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

------

##### [**Table of Contents**](#toc)

---

| | | |
|:---|:---|:---|
| **Exhibit No.** | **Description** | **Incorporation by Reference** |
| &nbsp;&nbsp;&nbsp;&nbsp;1.1 | Underwriting Agreement, dated August 12, 2021, by and between the Company and Northland, as representative of the several underwriters. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000262/ex1-1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;2.1 | Business Combination Agreement, dated as of December 17, 2021, by and among Armada Acquisition Corp. I, Rezolve Group Limited, Rezolve Merger Sub, Inc. and Rezolve Limited. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on December 17, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000359/ex2-1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;2.2 | First Amendment to Business Combination Agreement, dated as of November 9, 2022, by and among Armada Acquisition Corp. I, Rezolve Limited | [Previously filed as an exhibit to our Current Report of Form 8-K filed on November 14, 2022 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000119312522284842/d337253dex22.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;3.1 | Second Amended and Restated Certificate of Incorporation. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000262/ex3-1.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;3.2 | First Amendment to Second Amended and Restated Certificate of Incorporation | [Previously filed as an exhibit to our Current Report on Form 8-K filed on February 3, 2023 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000119312523023444/d418788dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;3.3 | Bylaws. | [Previously filed as an exhibit to our Registration Statement on Form S-1 on July 2, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000185/ex3-3.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | Warrant Agreement, dated August 12, 2021, by and between the Company and Continental Stock Transfer & Trust Company ("CST"), as warrant agent. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000262/ex4-1.htm) |
| 10.1 | Letter Agreement, dated August 12, 2021, by and among the Company, its officers, its directors, and the Sponsor. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000262/ex10-1.htm) |
| 10.2 | Investment Management Trust Agreement, dated August 12, 2021, by and between the Company and CST, as trustee. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000262/ex10-2.htm) |
| 10.3 | Registration Rights Agreement, dated August 12, 2021, by and between the Company, its officers, its directors, Armada Sponsor LLC (the "Sponsor") and EarlyBirdCapital, Inc. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000262/ex10-3.htm) |
| 10.4 | Administrative Services Agreement, dated August 12, 2021, by and between the Company and the Sponsor. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000262/ex10-4.htm) |
| 10.5 | Private Placement Shares Purchase Agreement, dated August 12, 2021, by and between the Company and the Sponsor. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000262/ex10-5.htm) |

---

------

##### [**Table of Contents**](#toc)

---

| | | |
|:---|:---|:---|
| **Exhibit No.** | **Description** | **Incorporation by Reference** |
| &nbsp;&nbsp;&nbsp;&nbsp;10.6 | Stock Escrow Agreement, dated August 12, 2021, by and between the Company, its directors, its officers, the Sponsor and CST. | [Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein.](http://www.sec.gov/Archives/edgar/data/1844817/000095015921000262/ex10-6.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;10.8 | [Form of Non-Redemption Agreement and Assignment of Economic Interest Business Combination Marketing Agreement, dated August 12, 2021, by and between the Company and Northland.](d431131dex108.htm) | Filed herewith. Previously filed as an exhibit to our Current Report on Form 8-K filed on August 18, 2021 and incorporated by reference herein. |
| &nbsp;&nbsp;&nbsp;&nbsp;31.1 | [Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)- 14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](d431131dex311.htm) | Filed herewith. |
| &nbsp;&nbsp;&nbsp;&nbsp;31.2 | [Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)- 14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](d431131dex312.htm) | Filed herewith. |
| &nbsp;&nbsp;&nbsp;&nbsp;32.1 | [Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](d431131dex321.htm) | Filed herewith. |
| &nbsp;&nbsp;&nbsp;&nbsp;32.2 | [Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](d431131dex322.htm) | Filed herewith. |
| 101.INS | XBRL Instance Document | Filed herewith. |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | Filed herewith. |
| 101.SCH | XBRL Taxonomy Extension Schema Document | Filed herewith. |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | Filed herewith. |
| 101.LAB | XBRL Taxonomy Extension Labels Linkbase Document | Filed herewith. |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | Filed herewith. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). | Filed herewith. |

---

------

##### [**Table of Contents**](#toc)

#### SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ARMADA ACQUISITION CORP. I** | **ARMADA ACQUISITION CORP. I** |
| Date: February 14, 2023 | By: | /s/ Stephen P. Herbert |
|  | Name: | Stephen P. Herbert |
|  | Title: | Chief Executive Officer |
|  |  | (Principal Executive Officer) |
| Date: February 14, 2023 | By: | /s/ Douglas M. Lurio |
|  | Name: | Douglas M. Lurio |
|  | Title: | President |
|  |  | (Principal Accounting and Financial Officer) |

---

## Exhibit 10.8

**Exhibit 10.8** 

***Execution Version***

**NON-REDEMPTION AGREEMENT AND ASSIGNMENT OF ECONOMIC INTEREST** 

This Non-Redemption Agreement and Assignment of Economic Interest (this "<u>Agreement</u>") is entered as of February 1, 2023 by and among Armada Acquisition Corp. I ("<u>AACI</u>"), Armada Sponsor, LLC (the "<u>Sponsor</u>") and the undersigned investor ("<u>Investor</u>").

**RECITALS** 

**WHEREAS**, the Sponsor currently holds shares of AACI common stock, $0.0001 par value per share, initially purchased in a private placement prior to AACI's initial public offering (the "<u>Founder Shares</u>");

**WHEREAS**, AACI expects to hold an annual meeting of stockholders (the "<u>Meeting</u>") for the purpose of approving, among other things, an amendment to AACI's Amended and Restated Certificate of Incorporation (the "<u>Charter</u>") to extend the date by which AACI must consummate an initial business combination (the "<u>Initial Business Combination</u>") for up to six additional months until as late as August 17, 2023 (the "<u>Extension</u>");

**WHEREAS**, the Charter provides that a stockholder of AACI may redeem its shares of AACI common stock, par value $0.0001 per share, initially sold as part of the units in AACI's initial public offering (whether they were purchased in our initial public offering or thereafter in the open market) (the "<u>Public Shares</u>" and together with the Founder Shares, the "<u>Common Shares</u>") in connection with the Charter amendment, on the terms set forth in the Charter ("<u>Redemption Rights</u>");

**WHEREAS**, subject to the terms and conditions of this Agreement, the Sponsor desires to transfer to Investor, and Investor desires to acquire from the Sponsor, that number of Founder Shares set forth opposite such Investor's name on <u>Exhibit A</u> (the "<u>Assigned Securities</u>"), to be transferred to Investor in connection with AACI's completion of its Initial Business Combination, and, prior to the transfer of the Assigned Securities to Investor, the Sponsor desires to assign the economic benefits of the Assigned Securities to Investor.

**NOW THEREFORE**, in consideration of the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Investor and the Sponsor hereby agree as follows:

1. <u>Terms of Transfer</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1. Upon the terms and subject to the conditions of this Agreement, the Sponsor agrees that if (a) as of 5:00
PM, New York time, on the date of the Meeting, Investor holds the Investor Shares (as defined below), (b) Investor does not exercise (or exercises and validly rescinds) its Redemption Rights with respect to such Investor Shares in connection with
the Meeting, and (c) the Extension is

------

approved at the Meeting and is effected by AACI's filing with the Secretary of State of the State of Delaware of a Certificate of Amendment to the Charter, then the Sponsor hereby agrees to assign to Investor for no additional consideration the Assigned Securities set forth on <u>Exhibit A</u>, and the Sponsor agrees to assign to Investor the Economic Interest (as defined below) associated with the Assigned Securities that the Sponsor has agreed to assign to Investor. "Investor Shares" shall mean the lesser of (i) 350,000 Public Shares, and (ii) 9.9% of the Public Shares that are not to be redeemed, including those Public Shares subject to non-redemption agreements with other AACI stockholders similar to this Agreement as of February 2, 2023. The Sponsor and AACI agree to provide Investor with the final number of Investor Shares subject to this Agreement no later than 9:00 a.m. Eastern on February 2, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2. The Sponsor and Investor hereby agree that the assignment of the Assigned Securities shall be subject to the
conditions that (i) the Initial Business Combination is consummated; and (ii) Investor (or its Permitted Transferees (as such term is defined in the Amended and Restated Limited Liability Company Agreement of the Sponsor (as it exists on
the date hereof, the " <u>Sponsor LLC Agreement</u> ")) executes a joinder as described in Section 1.8 hereof to that certain Letter Agreement, dated August 12, 2021 (as it exists on the date hereof, the " <u>Letter Agreement</u> "), by and among the Company, the Sponsor, officers and directors of the Company, and the other stockholders of the Company signatory thereto or, if the Letter Agreement is terminated or superseded in connection with the closing of
an Initial Business Combination, any successor agreement to the Letter Agreement with the public company resulting from such Initial Business Combination to which the Sponsor and the Founder Shares become subject, provided that (x) the Sponsor
and Founder Shares are not afforded more favorable terms than the Investor and the Assigned Securities under such successor agreement or any other agreement impacting the terms of such successor agreement and (y) the Investor shall not be
subject to any obligations under such successor agreement other than any limitations on transfer contained in such successor agreement and then solely with respect to the Assigned Securities (which limitations on transfer shall not be more
restrictive in any material respect and shall not impose a period restricting transfers exceeding 180 days from the date of closing the Initial Business Combination) or the registration rights with respect to the Assigned Securities contained in the
Registration Rights Agreement (as defined below) (such successor agreement and the Registration Rights Agreement, the " <u>Successor Agreements</u> "). Upon the satisfaction of the foregoing conditions, as applicable, the Sponsor shall
promptly transfer the Assigned Securities to Investor (or its Permitted Transferees). The Sponsor covenants and agrees to facilitate such transfer to Investor (or its Permitted Transferees) in accordance with the foregoing.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3. <u>Adjustment to Share Amounts</u>. If at any time the number of outstanding Founder Shares is increased or
decreased by a consolidation, combination, split or reclassification of the Common Shares or other similar event, then, as of the effective date of such consolidation, combination, split, reclassification or similar event, all share numbers
referenced in this Agreement shall be adjusted in proportion to such increase or decrease in outstanding Common Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4. <u>Merger or Reorganization, etc</u>. If there shall occur any reorganization, recapitalization,
reclassification, consolidation or merger involving AACI in which its Common Shares are converted into or exchanged for securities, cash or other property, then, following any such reorganization, recapitalization, reclassification, consolidation or
merger, in lieu of Common Shares, the Sponsor shall transfer, with respect to each Founder Share to be transferred hereunder, upon the Sponsor's receipt thereof, the kind and amount of securities, cash or other property into which such Assigned
Securities converted or exchanged.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5. <u>Forfeitures, Transfers, etc.</u> Investor shall not be required to forfeit or transfer the Assigned
Securities. Investor acknowledges that, pursuant to the Sponsor LLC Agreement, prior to, or at the time of, the Initial Business Combination, the Managers of the Sponsor have the authority to cause the Sponsor to subject the Founder Shares to
earn-outs, forfeitures, transfers or other restrictions, or amend the terms under which the Founder Shares were issued or any restrictions or other provisions relating to the Founder Shares set forth in the instruments establishing the same
(including voting in favor of any such amendment) or enter into any other arrangements with respect to the Founder Shares, and that the Managers are authorized to effectuate such earn-outs, forfeitures, transfers, restrictions, amendments or
arrangements, including arrangements relating to the relaxation or early release of restrictions, in such amounts and pursuant to such terms as they determine in their sole and absolute discretion for any reason. Sponsor acknowledges and agrees that
any such earn-outs, forfeitures, transfers, restrictions, amendments or arrangements shall apply only to the Founder Shares other than the Assigned Securities and the terms and conditions applicable to the Assigned Securities shall not be changed as
a result of any such earn-outs, forfeitures, transfers, restrictions, amendments or arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6. <u>Delivery of Shares; Other Documents.</u> At the time of the transfer of Assigned Securities hereunder, the
Sponsor shall deliver the Assigned Securities to Investor by transfer of book-entry shares effected through AACI's transfer agent. The parties to this Agreement agree to execute, acknowledge and deliver such further instruments and to do all
such other acts, as may be necessary or appropriate to carry out the purposes and intent of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7. <u>Assignment of Registration Rights</u>. Concurrent with the transfer of Assigned Securities to Investor under
this Agreement, the Sponsor hereby assigns all of its rights, duties and obligations to Investor with respect to the Assigned Securities under that certain Registration Rights Agreement, dated August 12, 2021 (as it exists on the date of the
Agreement, the " <u>Registration Rights</u> 

------

 <u>Agreement</u>"), by and among the Company, the Sponsor, and the other stockholders of the Company signatory thereto, and hereby represents and confirms to Investor that, upon Investor's receipt of the Assigned Securities, (i) Investor shall be an "Investor" under the Registration Rights Agreement and (ii) the Assigned Securities shall be "Registrable Securities" under the Registration Rights Agreement. This agreement constitutes the Sponsor's written notice to AACI of such assignment in accordance with the Registration Rights Agreement (if required). Investor shall provide to AACI a written agreement in accordance with the Registration Rights Agreement as described in Section 1.8 agreeing to be bound by the terms and provisions of the Registration Rights Agreement as an "Investor" thereunder with respect to the Assigned Securities (upon acquisition thereof) as "Registrable Securities" thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8. <u>Joinder</u>. In connection with the transfer of the Assigned Securities to Investor, Investor and AACI shall
execute a joinder to the Letter Agreement and the Registration Rights Agreement (or the Successor Agreements, as applicable) in substantially the form attached hereto as <u>Exhibit B</u> (the " <u>Joinder</u> ") pursuant to which Investor
shall agree with AACI to (i) be bound solely by Section 5(b) of the Letter Agreement solely with respect to the Assigned Securities, and with respect thereto, as though the undersigned was an original party to, and bound, solely by
Section 1(C) of the Subscription Agreement referenced in such Section 5(b), or if a Successor Agreement is executed in connection with the closing of an Initial Business Combination, solely by the limitations on transfer contained in such
Successor Agreement solely with respect to the Assigned Securities and which limitations on transfer shall not be more restrictive in any material respect and shall not impose a period restricting transfers exceeding 180 days from the date of
closing the Initial Business Combination, and (ii) be bound by the terms and provisions of the Registration Rights Agreement as an "Investor" thereunder with respect to the Assigned Securities (upon acquisition thereof) as
"Registrable Securities" thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9. <u>Termination</u>. This Agreement and each of the obligations of the undersigned shall terminate on earlier of
(a) the failure of AACI's stockholders to approve the Extension at the Meeting, or the determination of AACI not to proceed to effect the Extension, (b) the fulfillment of all obligations of parties hereto, (c) the liquidation or
dissolution of AACI, or (d) the mutual written agreement of the parties hereto.

2. <u>Assignment of Economic Interest</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1. Upon satisfaction of the conditions set forth in Section 1.1, the Sponsor hereby assigns to Investor all
of its economic right, title and interest in and to that number of Assigned Securities set forth on <u>Exhibit A</u> (the " <u>Economic Interest</u> "), subject to adjustment as set forth in Section 2.2. The Economic Interest represents
the Sponsor's right to receive dividends and other distributions made by the Sponsor pursuant to the Sponsor LLC Agreement allocated to that number of Assigned Securities set forth on <u>Exhibit A</u> represented by the Founder Shares held
directly by the Sponsor.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2. If at any time the number of outstanding shares of common stock of AACI is increased or decreased by a
consolidation, combination, split or reclassification or other similar event, then, as of the effective date of such consolidation, combination, split, reclassification or similar event, the number of shares underlying the Economic Interest shall be
adjusted in proportion to such increase or decrease in outstanding shares of common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3. Investor acknowledges and agrees that it has no right to vote on matters of the Sponsor as a result of the
Assigned Securities or Economic Interest, or to vote with respect to any Assigned Securities, and it has no right to vote Assigned Securities prior to transfer of any such shares to Investor pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4. Investor acknowledges and agrees that if it has a right pursuant to its Economic Interest to receive any
dividends or other distributions paid in shares of common stock or other non-cash property that is subject to the transfer restrictions and/or the lockup period set forth in Section 5(b) of the Letter
Agreement (or, if applicable, in the Successor Agreements), the Sponsor shall transfer all of its right, title and interest in such dividends or distributions concurrently with the transfer of the Assigned Securities to such Investor pursuant to
Section 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5. If the conditions to the transfer of the Founder Shares in Section 1 are not satisfied with respect to any
Founder Shares, then Investor shall automatically assign its Economic Interests in such Founder Shares back to the Sponsor, for no consideration.

3. <u>Representations</u> *<u> </u>* <u>and Warranties of Investor</u>. Investor represents and warrants to,
and agrees with, the Sponsor that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1. <u>No Government Recommendation or Approval</u>. Investor understands that no federal or state agency has
passed upon or made any recommendation or endorsement of the offering of the Assigned Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2. <u>Accredited Investor</u>. Investor is an "accredited investor" as such term is defined in Rule
501(a) of Regulation D under the Securities Act of 1933, as amended (the " <u>Securities Act</u> "), and acknowledges that the sale contemplated hereby is being made in reliance, among other things, on a private placement exemption to
"accredited investors" under the Securities Act and similar exemptions under state law.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3. <u>Intent</u>. Investor is acquiring the Assigned Securities solely for investment purposes, for such
Investor's own account (and/or for the account or benefit of its members or affiliates, as permitted), and not with a view to the distribution thereof in violation of the Securities Act and Investor has no present arrangement to sell Assigned
Securities to or through any person or entity except as may be permitted hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4. <u>Restrictions on Transfer; Trust Account; Redemption Rights</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.1. Investor acknowledges and agrees that, prior to their transfer hereunder, the Assigned Securities are, and
following any transfer to Investor may continue to be, subject to the restrictions on transfer set forth in Section 5(b) of the Letter Agreement (or 1(C) of the Subscription Agreement referenced therein), or, if applicable, the Successor
Agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.2. Investor acknowledges and agrees that the Assigned Securities are not entitled to, and have no right, interest
or claim of any kind in or to, any monies held in the trust account into which the proceeds of AACI's initial public offering were deposited (the " <u>Trust Account</u> ") or distributed as a result of any liquidation of the Trust
Account.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.3. Investor waives any right that it may have to elect to have AACI redeem any Investor Shares and agrees not to
redeem or otherwise exercise any right to redeem, the Investor Shares and to reverse and revoke any prior redemption elections made with respect to the Investor Shares in connection with the Extension. For the avoidance of doubt, nothing in this
Agreement is intended to restrict or prohibit Investor's ability to redeem any Public Shares other than the Investor Shares, or to trade or redeem any Public Shares (other than the Investor Shares) in its discretion and at any time or any
Investor Shares in its discretion and at any time after February 2, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.4. Investor acknowledges and understands the Assigned Securities are being offered in a transaction not involving
a public offering in the United States within the meaning of the Securities Act and have not been registered under the Securities Act and, if in the future Investor decides to offer, resell, pledge or otherwise transfer Assigned Securities, such
Assigned Securities may be offered, resold, pledged or otherwise transferred only (A) pursuant to an effective registration statement filed under the Securities Act, (B) pursuant to an exemption from registration under Rule 144 promulgated
under the Securities Act, if available, or (C) pursuant to any other available exemption from the registration requirements of the Securities Act, and in each case in accordance with any applicable securities laws of any state or any other
jurisdiction. Investor agrees that, if any transfer of the Assigned Securities or any interest therein is proposed to be made, as a condition precedent to any such transfer, Investor may be required to deliver to AACI an opinion of counsel
satisfactory to AACI that registration is not required with respect to the Assigned Securities to be transferred. Absent registration or another available exemption from registration, Investor agrees it will not transfer the Assigned
Securities.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5. <u>Voting</u>. Investor agrees that it will and will cause its controlled affiliates to vote (or cause to be
voted) or execute and deliver a written consent (or cause a written consent to be executed and delivered) all of AACI Common Shares owned, as of the applicable record date, by any of them at the Meeting in favor of the Extension and cause all such
shares to be counted as present at the Meeting for purposes of establishing a quorum.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6. <u>Sophisticated Investor</u>. Investor is sophisticated in financial matters and able to evaluate the risks
and benefits of the investment in the Assigned Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7. <u>Risk of Loss</u>. Investor is aware that an investment in the Assigned Securities is highly speculative and
subject to substantial risks. Investor is cognizant of and understands the risks related to the acquisition of the Assigned Securities, including those restrictions described or provided for in this Agreement, the Sponsor LLC Agreement and the
Letter Agreement (or, if applicable, the Successor Agreements). Investor is able to bear the economic risk of its investment in the Assigned Securities for an indefinite period of time and able to sustain a complete loss of such investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8. <u>Independent Investigation</u>. Investor has relied upon an independent investigation of AACI and has not
relied upon any information or representations made by any third parties or upon any oral or written representations or assurances, express or implied, from the Sponsor or any representatives or agents of the Sponsor, other than as set forth in this
Agreement. Investor is familiar with the business, operations and financial condition of AACI and has had an opportunity to ask questions of, and receive answers from AACI's management concerning AACI and the terms and conditions of the
proposed sale of the Assigned Securities and has had full access to such other information concerning AACI as Investor has requested. Investor confirms that all documents that it has requested have been made available and that Investor has been
supplied with all of the additional information concerning this investment which Investor has requested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9. <u>Organization and Authority</u>. If any entity, Investor is duly organized and existing under the laws of the
jurisdiction in which it was organized and it possesses all requisite power and authority to acquire the Assigned Securities, enter into this Agreement and perform all the obligations required to be performed by Investor hereunder.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10. <u>Non-U.S. Investor</u>. If Investor is not a United States person (as
defined by Section 7701(a)(30) of the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder (collectively, the " <u>Code</u> ")), Investor hereby represents that it has satisfied itself as to the
full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Assigned Securities or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the acquisition of the
Assigned Securities, (ii) any foreign exchange restrictions applicable to such acquisition, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be
relevant to the acquisition, holding, redemption, sale, or transfer of the Assigned Securities. Investor's subscription and payment for and continued beneficial ownership of the Assigned Securities will not violate any applicable securities or
other laws of Investor's jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11. <u>Authority</u>. This Agreement has been validly authorized, executed and delivered by Investor and is a valid
and binding agreement enforceable in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance, moratorium, reorganization, or similar laws relating to, or affecting generally
the enforcement of, creditors' rights and remedies or by equitable principles of general application and except as enforcement of rights to indemnity and contribution may be limited by federal and state securities laws or principles of public
policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12. <u>No Conflicts</u>. The execution, delivery and performance of this Agreement and the consummation by Investor
of the transactions contemplated hereby do not violate, conflict with or constitute a default under (i) Investor's organizational documents, (ii) any agreement or instrument to which Investor is a party or (iii) any law, statute,
rule or regulation to which Investor is subject, or any order, judgment or decree to which Investor is subject, in the case of clauses (ii) and (iii), that would reasonably be expected to prevent Investor from fulfilling its obligations under
this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13. <u>No Advice from Sponsor</u>. Investor has had the opportunity to review this Agreement and the transactions
contemplated by this Agreement, the Sponsor LLC Agreement and the form of Letter Agreement with Investor's own legal counsel and investment and tax advisors. Except for any statements or representations of the Sponsor explicitly made in this
Agreement, Investor is relying solely on such counsel and advisors and not on any statements or representations, express or implied, of the Sponsor or any of its representatives or agents for any reason whatsoever, including without limitation for
legal, tax or investment advice, with respect to this investment, the Sponsor, AACI, the Assigned Securities, the transactions contemplated by this Agreement or the securities laws of any jurisdiction.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.14. <u>Reliance on Representations and Warranties</u>. Investor understands that the Assigned Securities are being
offered and sold to Investor in reliance on exemptions from the registration requirements under the Securities Act, and analogous provisions in the laws and regulations of various states, and that the Sponsor is relying upon the truth and accuracy
of the representations, warranties, agreements, acknowledgments and understandings of Investor set forth in this Agreement in order to determine the applicability of such provisions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.15. <u>No General Solicitation</u>. Investor is not subscribing for Assigned Securities as a result of or
subsequent to any general solicitation or general advertising, including but not limited to any advertisement, article, notice or other communication published in any newspaper, magazine, or similar media or broadcast over television or radio or any
seminar or meeting whose attendees have been invited by any general solicitation or general advertising.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.16. <u>Brokers</u>. No broker, finder or intermediary has been paid or is entitled to a fee or commission from or
by Investor in connection with the acquisition of the Assigned Securities nor is Investor entitled to or will accept any such fee or commission.

4. <u>Representations</u> *<u> </u>* <u>and Warranties of Sponsor.</u> The Sponsor represents and warrants to,
and agrees with, the Investor that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1. <u>Power and Authority</u>. The Sponsor is a limited liability company duly formed and validly existing and in
good standing as a limited liability company under the laws of the State of Delaware and possesses all requisite limited liability company power and authority to enter into this Agreement and to perform all of the obligations required to be
performed by the Sponsor hereunder, including the assignment, sale and transfer the Assigned Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2. <u>Authority</u>. All corporate action on the part of the Sponsor and its officers, directors and members
necessary for the authorization, execution and delivery of this Agreement and the performance of all obligations of the Sponsor required pursuant hereto has been taken. This Agreement has been duly executed and delivered by the Sponsor and (assuming
due authorization, execution and delivery by Investor) constitutes the Sponsor's legal, valid and binding obligation, enforceable against the Sponsor in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, fraudulent conveyance, moratorium, reorganization, or similar laws relating to, or affecting generally the enforcement of, creditors' rights and remedies or by equitable principles of general application and except as
enforcement of rights to indemnity and contribution may be limited by federal and state securities laws or principles of public policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3. <u>Title to Securities</u>. The Sponsor is the record and beneficial owner of, and has good and marketable
title to, the Assigned Securities and will, immediately prior to the transfer of the Assigned Securities to Investor, be the record and beneficial owner of the Assigned Securities, in each case, free and clear of all

------

liens, pledges, security interests, charges, claims, encumbrances, agreements, options, voting trusts, proxies and other arrangements or restrictions of any kind (other than transfer restrictions and other terms and conditions that apply to the Founder Shares generally and applicable securities laws). The Assigned Securities to be transferred, when transferred to Investor as provided herein, will be free and clear of all liens, pledges, security interests, charges, claims, encumbrances, agreements, options, voting trusts, proxies and other arrangements or restrictions of any kind (other than transfer restrictions under the Letter Agreement (or, if applicable, the Successor Agreements) and applicable securities laws).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4. <u>No Conflicts</u>. The execution, delivery and performance of this Agreement and the consummation by the
Sponsor of the transactions contemplated hereby do not violate, conflict with or constitute a default under (i) the certificate of formation or the Sponsor LLC Agreement, (ii) any agreement or instrument to which the Sponsor is a party or
by which it is bound (including the Sponsor LLC Agreement, the Letter Agreement and, if applicable, the Successor Agreements) or (iii) any law, statute, rule or regulation to which the Sponsor is subject or any order, judgment or decree to
which the Sponsor is subject. The Sponsor is not required under federal, state or local law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or
self-regulatory entity in order for it to perform any of its obligations under this Agreement or transfer the Assigned Securities in accordance with the terms hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5. <u>No General Solicitation</u>. The Sponsor has not offered the Assigned Securities by means of any general
solicitation or general advertising within the meaning of Regulation D of the Securities Act, including but not limited to any advertisement, article, notice or other communication published in any newspaper, magazine, or similar media or broadcast
over television or radio or any seminar or meeting whose attendees have been invited by any general solicitation or general advertising.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6. <u>Brokers</u>. No broker, finder or intermediary has been paid or is entitled to a fee or commission from or
by the Sponsor in connection with the sale of the Assigned Securities nor is the Sponsor entitled to or will accept any such fee or commission.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7. <u>Transfer Restrictions</u>. Until termination of this Agreement, the Sponsor shall not transfer any of its
Founder Shares representing the economic benefit of the Assigned Securities other than any transfer pursuant to the Sponsor LLC Agreement in connection with an Initial Business Combination.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8. <u>Reliance on Representations and Warranties</u>. The Sponsor understands and acknowledges that Investor is
relying upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of the Sponsor set forth in this Agreement.

5. <u>Trust Account</u>. Until the earlier of (a) the consummation of AACI's initial business
combination; (b) the liquidation of the Trust Account; and (c) 24 months from consummation of AACI's initial public offering, AACI will maintain the investment of funds held in the Trust Account in interest-bearing United States government
securities within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended, having a maturity of 185 days or less, or in money market funds meeting the conditions of paragraphs (d)(1), (d)(2), (d)(3) and (d)(4) of Rule 2a-7 promulgated under the Investment Company Act of 1940, as amended, which invest only in direct U.S. government treasury obligations. AACI further confirms that, in order to mitigate the current uncertainty
surrounding the implementation of the Inflation Reduction Act of 2022, in the event that the Extension is approved and implemented as described in the Definitive Proxy Statement, funds in trust, including any interest thereon, will not be used to
pay for any excise tax liabilities with respect to any redemptions that occur after December 31, 2022 and prior to or in connection with a Business Combination or liquidation of the Company.

6. <u>Governing Law; Jurisdiction; Waiver of Jury Trial</u>. This Agreement shall be governed by and construed and
enforced in accordance with the laws of the State of New York, without giving effect to its principles or rules of conflict of laws to the same extent such principles or rules would require or permit the application of the laws of another
jurisdiction. The parties hereto hereby waive any right to a jury trial in connection with any litigation pursuant to this Agreement and the transactions contemplated hereby. With respect to any suit, action or proceeding relating to the
transactions contemplated hereby, the undersigned irrevocably submit to the jurisdiction of the United States District Court or, if such court does not have jurisdiction, the New York state courts located in the Borough of Manhattan, State of New
York, which submission shall be exclusive.

7. <u>Assignment; Entire Agreement; Amendment</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1. <u>Assignment</u>. Any assignment of this Agreement or any right, remedy, obligation or liability arising
hereunder by either the Sponsor or Investor to any person that is not an affiliate of such party shall require the prior written consent of the other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2. <u>Entire Agreement</u>. This Agreement sets forth the entire agreement and understanding between the parties
as to the subject matter thereof and merges and supersedes all prior discussions, agreements and understandings of any and every nature among them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3. <u>Amendment</u>. Except as expressly provided in this Agreement, neither this Agreement nor any term hereof
may be amended, waived, discharged or terminated other than by a written instrument signed by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4. <u>Binding upon Successors</u>. This Agreement shall be binding upon and inure to the benefit of the
parties hereto and to their respective heirs, legal representatives, successors and permitted assigns.

8. <u>Notices</u>. Unless otherwise provided herein, any notice or other communication to a party hereunder shall
be sufficiently given if in writing and personally delivered or sent by facsimile or other electronic transmission with copy sent in another manner herein provided or sent by courier (which for all purposes of this Agreement shall include Federal
Express or another recognized overnight courier) or mailed to said party by certified mail, return receipt requested, at its address provided for herein or such other address as either may designate for itself in such notice to the other.
Communications shall be deemed to have been received when delivered personally, on the scheduled arrival date when sent by next day or 2nd-day courier service, or if sent by facsimile upon receipt of
confirmation of transmittal or, if sent by mail, then three days after deposit in the mail. If given by electronic transmission, such notice shall be deemed to be delivered (a) if by electronic mail, when directed to an electronic mail address
at which the party has provided to receive notice; and (b) if by any other form of electronic transmission, when directed to such party.

9. <u>Counterparts</u>. This Agreement may be executed in two or more counterparts, all of which when taken
together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart.
Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

10. <u>Survival; Severability</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1. <u>Survival</u>. The representations, warranties, covenants and agreements of the parties hereto shall survive
the closing of the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2. <u>Severability</u>. In the event that any provision of this Agreement becomes or is declared by a court of
competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability shall be effective if it materially changes the economic benefit of this
Agreement to any party.

------

11. <u>Headings</u> *.* The titles and subtitles used in this Agreement are used for convenience only and are
not to be considered in construing or interpreting this Agreement.

12. <u>No Publicity; Disclosure</u>. The Sponsor agrees that it will not, without the prior written consent of
Investor, publicly disclose the name of Investor or any of its affiliates or investment advisors, other than as required by applicable law, rule or regulation, in which case Sponsor shall provide Investor with prior written notice of such
disclosure. The Company shall, by 9:00 a.m., New York City time, on the first business day immediately following the date of this Agreement, issue one or more press releases or file with the United States Securities and Exchange Commission a Current
Report on Form 8-K (collectively, the " <u>Disclosure Document</u> ") disclosing, to the extent not previously publicly disclosed, all material terms of the transactions contemplated hereby and any
other material, nonpublic information that the Company has provided to Investor at any time prior to the filing of the Disclosure Document. The Disclosure Document shall also provide that until the earlier of (a) the consummation of AACI's
initial business combination; (b) the liquidation of the Trust Account; and (c) 24 months from consummation of AACI's initial public offering, AACI will maintain the investment of funds held in the Trust Account in interest-bearing United
States government securities within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended, having a maturity of 185 days or less, or in money market funds meeting the conditions of paragraphs (d)(1), (d)(2), (d)(3)
and (d)(4) of Rule 2a-7 promulgated under the Investment Company Act of 1940, as amended, which invest only in direct U.S. government treasury obligations. Such Disclosure Document shall further provide
confirmation by AACI that, in order to mitigate the current uncertainty surrounding the implementation of the Inflation Reduction Act of 2022, in the event that the Extension is approved and implemented as described in the Definitive Proxy
Statement, funds in trust, including any interest thereon, will not be used to pay for any excise tax liabilities with respect to any redemptions that occur after December 31, 2022 and prior to or in connection with a Business Combination or
liquidation of the Company. Upon the issuance of the Disclosure Document, to the Company's knowledge, Investor shall not be in possession of any material, nonpublic information received from the Company or any of its officers, directors or
employees.

13. <u>Independent Nature of Rights and Obligations</u>. Nothing contained herein, and no action taken by any party
pursuant hereto, shall be deemed to constitute Investor and the Sponsor as, and the Sponsor acknowledges that Investor and the Sponsor do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a
presumption that Investor and the Sponsor are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement or any matters, and the Sponsor acknowledges that Investor and the Sponsor
are not acting in concert or as a group, and the Sponsor shall not assert any such claim, with respect to such obligations or the transactions contemplated by this Agreement.

------

14. <u>Most Favored Nation</u>. In the event the Sponsor enters one or more other non-redemption agreements before or after the execution of this Agreement in connection with the Meeting, the Sponsor represents that the terms of such other agreements are not materially more favorable to
such other investors thereunder than the terms of this Agreement are in respect of the Investor. In the event that another investor is afforded any such more favorable terms than the Investor, the Sponsor shall promptly inform the Investor of such
more favorable terms in writing, and the Investors shall have the right to elect to have such more favorable terms included herein, in which case the parties hereto shall promptly amend this Agreement to effect the same.

------

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

---

| |
|:---|
| **INVESTOR** |
| **[Investor]** |
|  By: |
|  Name: |
|  Title: |

---

*[Signature Page to Non-Redemption Agreement]* 

------

---

| | |
|:---|:---|
| **SPONSOR:** | **SPONSOR:** |
| ARMADA SPONSOR, LLC | ARMADA SPONSOR, LLC |
|  By: |  |
| Name: | Stephen Herbert |

---

*[Signature Page to Non-Redemption Agreement]* 

------

---

| | |
|:---|:---|
| **AACI:** | **AACI:** |
| ARMADA ACQUISITION CORP. I | ARMADA ACQUISITION CORP. I |
|  By: |  |
| Name: | Stephen Herbert |
|  Title: | Chief Executive Officer and Chairman |

---

*[Signature Page to Non-Redemption Agreement]* 

------

<u>Exhibit A</u> 

---

| | | |
|:---|:---|:---|
| **Investor** | **Founder Shares<br>to be Transferred<br>/ Economic<br>Interest<br>Assigned<sup>1</sup>** | **Number of<br>Public Shares to<br>be Held as<br>Investor<br>Shares<sup>2</sup>** |
|  **[Investor]** |  |  |
|  Address: | 75000 | 350000 |
|  SSN/EIN: |  |  |

---

------

<sup>1</sup> Equal to 1 Founder Share for every 4.66666 Investor Shares, up to 75,000 Founder Shares.

<sup>2</sup> Equal to the lesser of (i) 350,000 Public Shares, and (ii) 9.9% of the Public Shares subject to non-redemption agreements with other AACI stockholders similar to this Agreement as of February 2, 2023. 

------

EXHIBIT B

FORM OF JOINDER

TO

LETTER AGREEMENT

AND

REGISTRATION RIGHTS AGREEMENT

______, 20_

Reference is made to that certain Non-Redemption Agreement and Assignment of Economic Interest, dated as of , 2023 (the "<u>Agreement</u>"), by and between ("<u>Investor</u>"), Armada Acquisition Corp. I (the "<u>Company</u>") and Armada Sponsor, LLC (the "<u>Sponsor</u>"), pursuant to which Investor acquired securities of the Company from the Sponsor. Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Agreement.

By executing this joinder, Investor hereby agrees, as of the date first set forth above, that Investor (i) shall become a party to that certain Letter Agreement, dated August 12, 2021 (as it exists on the date of the Agreement, the "<u>Letter Agreement</u>"), by and among the Company, the Sponsor, officers and directors of the Company, and the other stockholders of the Company signatory thereto, solely with respect to Section 5(b) of the Letter Agreement, and shall be bound by, and entitled to the rights provided under, the terms and provisions of such section of the Letter Agreement as an Insider (as defined therein) solely with respect to its Assigned Securities and with respect thereto, as though the undersigned was an original party to, and bound, solely by Section 1(C) of the Subscription Agreement referenced in such Section 5(b), except that if a Successor Agreement is executed in connection with the closing of an Initial Business Combination, Investor agrees to be bound solely by the limitations on transfer contained in such Successor Agreements solely with respect to its Assigned Securities (which limitations on transfer shall not be more restrictive in any material respect and shall not impose a period restricting transfers exceeding 180 days from the date of closing the Initial Business Combination), and (ii) shall become a party to that certain Registration Rights Agreement, dated August 12, 2021 (as it exists on the date of the Agreement, the "<u>Registration Rights Agreement</u>"), by and among the Company, the Sponsor, and the other stockholders of the Company signatory thereto, and shall be bound by the terms and provisions of the Registration Rights Agreement as an Investor (as defined therein) and entitled to the rights of an Investor under the Registration Rights Agreement and the Assigned Securities (together with any other equity security of the Company issued or issuable with respect to any such Assigned Securities by way

------

of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization) shall be "Registrable Securities" thereunder, except that if the Registration Rights Agreement is terminated or superseded in connection with the closing of an Initial Business Combination, Investor shall become a party to such successor agreement to the Registration Rights Agreement with the public company resulting from such Initial Business Combination to which the Sponsor and the Founder Shares become subject pursuant to which Investor agrees, solely with respect to the Assigned Securities, to be bound by the terms and provisions of the Registration Rights Agreement as an Investor or Holder (as defined therein, as applicable) and entitled to the rights of an Investor or Holder (as applicable) under the Registration Rights Agreement and the Assigned Securities (together with any other equity security of the Company issued or issuable with respect to any such Assigned Securities by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization) shall be "Registrable Securities" thereunder; provided that (x) the Sponsor and Founder Shares are not afforded more favorable terms than the Investor and the Assigned Securities under such successor agreement or any other agreement impacting the terms of such successor agreement and (y) the terms of such successor agreement shall not be materially less favorable to the Investor than those contained in the Successor Agreements.

For the purposes of clarity, it is expressly understood and agreed that each provision contained herein, in the Letter Agreement and, if applicable, the Successor Agreements (each to the same extent applicable to Investor) is between the Company and Investor, solely, and not between and among Investor and the other stockholders of the Company signatory thereto.

------

This joinder may be executed in two or more counterparts, and by facsimile, all of which shall be deemed an original and all of which together shall constitute one instrument.

---

| |
|:---|
|  **[INVESTOR]** |
| By: |
| Name: |
| Title: |

---

---

| | |
|:---|:---|
| **<u>ACKNOWLEDGED AND AGREED:</u>** | **<u>ACKNOWLEDGED AND AGREED:</u>** |
|  ARMADA ACQUISITION CORP. I | ARMADA ACQUISITION CORP. I |
| By: |  |
|  | Name: |
|  | Title: |

---

## Exhibit 31.1

**EXHIBIT 31.1** 

**CERTIFICATION** 

**PURSUANT TO RULES 13a-14(a) AND 15d-14(a)** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO** 

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002** 

I, Stephen P. Herbert, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Armada
Acquisition Corp. I;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal
control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant's internal controls over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: February 14, 2023 | By: | /s/ Stephen P. Herbert |
|  |  | Stephen P. Herbert |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

## Exhibit 31.2

**EXHIBIT 31.2** 

**CERTIFICATION** 

**PURSUANT TO RULES 13a-14(a) AND 15d-14(a)** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO** 

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002** 

I, Douglas M. Lurio, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Armada
Acquisition Corp. I;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal
control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant's internal controls over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: February 14, 2023 | By: | /s/ Douglas M. Lurio |
|  |  | Douglas M. Lurio |
|  |  | President |
|  |  | (Principal Financial and Accounting Officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1** 

**CERTIFICATION PURSUANT TO** 

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Quarterly Report of Armada Acquisition Corp. I (the "Company") on Form 10-Q for the quarterly period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Stephen P. Herbert, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.

Date: February 14, 2023

---

| | |
|:---|:---|
| /s/ Stephen P. Herbert | /s/ Stephen P. Herbert |
| Name: | Stephen P. Herbert |
| Title: | Chief Executive Officer |
|  | (Principal Executive Officer) |

---

## Exhibit 32.2

**EXHIBIT 32.2** 

**CERTIFICATION PURSUANT TO** 

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Quarterly Report of Armada Acquisition Corp. I (the "Company") on Form 10-Q for the quarterly period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Douglas M. Lurio, President of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.

Date: February 14, 2023

---

| | |
|:---|:---|
| /s/ Douglas M. Lurio | /s/ Douglas M. Lurio |
| Name: | Douglas M. Lurio |
| Title: | President |
|  | (Principal Financial and Accounting Officer) |

---